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ABSTRACT
Vibrio vulnificus is a Gram-negative organism that is found in estuarine environments.
The bacterium is capable of causing gastroenteritis, wound infections, and septicemia, often
resulting in death for susceptible individuals. Monoclonal antibodies (MAbs) to five
lipopolysaccharide (LPS) O-serovars have previously been used as a serotyping system in
epidemiological studies. Here is the first report of two additional MAbs capable of recognizing
two new LPS serovars (O6 and O7), further increasing the number of V. vulnificus that can be
typed. Analysis of V. vulnificus isolates from the United States, Europe, and Asia demonstrated
that the O1/O5 serovar is dominate in clinical isolates, serovars O3 and O4 are dominate in the
environmental isolates of Europe, and that most environmental isolates from United States are
nontypeable. Additionally, MAb, RS1, was chosen for further analysis by having DNA coding
for its light and heavy chains cloned into a phage-display system. The published primers,
designed to be used with the pComb3X display system, produced primer dimers and were
unsuccessful in generating the single chain variable fragment (scFv) to be cloned into the phage
vector. Modification of the existing primers inhibited the formation of primer dimers and
allowed for the successful generation of the scFv. The resulting phage-displayed antibody, PJ1,
displayed similar binding characteristics as RS1 showing the usefulness of phage-display as an
alternative method of maintaining pre-existing MAbs. Lastly, it was proposed that as V.
vulnificus undergoes capsular switching it is possible that LPS switching occurs as well. Analysis
of the data suggests that capsule and LPS switching are not directly related. Interestingly, LPS
switching seems to occur in a unidirectional manner on two separate branches that converge on
serovar O5 suggesting that O5 may be a group of sugars that are used as a building block for
other serovars. This allowed for the formation of a speculative LPS model. The stability of
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serovars O6 and O7 in the LPS switching assay make them difficult to place in relationship to
serovar O5 and further analysis will be needed to more accurately place them on the LPS model.
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CHAPTER 1:
REVIEW OF THE LITERATURE

1

Background
Until 1970, Vibrio isolates were classified into one of two categories: 1) Vibrio cholerae,
the etiological agent of epidemic cholera, and 2) non-agglutinable Vibrios, which consisted of a
group collectively known as the “non-cholerae Vibrios” (1). Because toxigenic V. cholerae O1 is
rarely seen in extraintestinal infections, researchers began to take interest in the non-agglutinable
Vibrios that were responsible for both diarrheal disease and extraintestinal infections such as
wound and ear infections, septicemia, and cholecystitis (2-4).
Initial classification systems of marine organisms resulted in organisms being placed in
Vibrio, Aeromonas, Pseudomonas, and Beneckea (5). An extensive study of marine organisms in
1973 (6), grouped 14 human, non-enteric isolates into a group designated C-2 based on
phenotypic traits. Further analysis of this group in 1976 (7) resulted in the recognition of a new
species, Beneckea vulnifica, based on in vitro DNA/DNA competition studies, a G/C content of
45-48%, and the presence of a single, sheathed, polar flagella (7). Although both B. vulnifica and
Beneckea parahaemolyticus utilized sucrose and grew at 40ºC, the two groups could be easily
distinguished based on their flagellation, cell curvature, and utilization of butyrate, heptanoate,
ethanol, L-serine, L-leucine, and putrescine (7).
While Reichelt et al. (7) were suggesting the new species B. vulnifica, an 11 year study of
isolates by Hollis et al. (8) resulted in a new classification of the genus Vibrio termed the L+
Vibrio (lactose fermenters). The newly identified group of Vibrio, L+ Vibrio, was similar to V.
parahaemolyticus and V. alginolyticus but differed in its ability to ferment the sugar lactose, the
production of β-D-galactosidase, and a NaCl tolerance of less than 8%. Twenty of the 38 isolates
of L+ Vibrio examined were isolated from blood and two were isolated from spinal fluid. Hollis
et al. (8) further suggested that many of the isolates from wound infections and septicemia that
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had been previously identified as variants of V. parahaemolyticus should probably be classified
as a sub-species of V. parahaemolyticus or its own distinct species.
Interestingly, the controversy surrounding the nomenclature of the bacterium B. vulnifica
as described by Reichelt et al. (7) and L+ Vibrio described by Hollis et al. (8) was finally
resolved when J.J. Farmer, III, proposed these two bacterium were the same and should be
classified as Vibrio vulnificus (9). Acceptance of this new nomenclature was not permanently
adopted until the abolition of the genus Beneckea in 1980 (10). Baumann et al. (10), described V.
vulnificus as an organism that contained a single, polar sheathed flagellum, had a G/C content of
47.2%, fermented glucose with no gas production, required a minimum of 140 mM of NaCl and
was oxidase positive.
The bacterium Vibrio (L. v. move rapidly back and forth) vulnificus (L. adj. inflicting
wounds) is described in Bergey’s Manual of Systematic Bacteriology (11) as belonging to the
Gamma-proteobacteria,

Gram-negative,

motile

rods,

mesophilic,

chemoorganotrophic,

facultative anaerobes, and being found in aquatic habitats and in association with eukaryotes.
Vibrio vulnificus is a free-living bacterium found in marine and estuarine environments
throughout the world (12-22) being isolated from waters where temperatures range from 9 to
31ºC and proliferates when water temperature exceeds 18ºC (23, 24). In the United States, it is
predominately found along the Gulf of Mexico, but it has also been isolated from the Pacific and
Atlantic coasts (13, 25-27).
While V. vulnificus can be present in marine waters any time of the year, the total number
of viable cells seems to rise and fall with water temperature. Once temperatures drop below 10ºC
the number of viable cells drops to nearly undetectable levels (25, 26). As a survival mechanism,
it appears that the bacterium goes into a viable but nonculturable state (VBNC) (28), resulting in
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the following morphological and biochemical changes: a transition from rods to cocci,
membrane fatty acid profiles (decrease in unsaturated fatty acids from 45 to 17%, and an
increase in saturated fatty acids from 49 to 69.5%), cell wall (increased resistance to sonication),
and reduced amino acid transport (29-31). V. vulnificus can be recovered from the VBNC by the
introduction of nutrient-free medium and an increase in temperature (32) which is similar to the
warming of coastal waters in the spring.
Vibrio vulnificus is found free-living in the marine environment, and it is often taken up
and concentrated in the tissues of filter-feeding organisms such as oysters, mussels, clams, and
scallops. Vibrio vulnificus has been found in oysters at concentrations as high as 106 bacteria per
gram of oyster tissue during periods of warm water temperature (33). While V. vulnificus is
generally associated with filter-feeding organisms, the bacterium has also been found in fish
species that frequent oyster reefs (34), shrimp (35, 36) and eels (12, 37-40) . It has been
suggested that fish may act as the primary transport for shuttling the bacterium between different
oyster reefs (41).
The Health Problem
The bacterium V. vulnificus is associated with three different types of infections in
humans: wound, gastroenteritis, and septicemia. Vibrio vulnificus infections, once credited to an
unnamed halophilic lactose-fermenting Vibrio species, was first described by Blake et al. (42).
Two distinct clinical presentations were noted. The first type of presentation was a septicemia
following the consumption of raw oysters 24 hours preceding the onset of symptoms. Eighteen
of 24 patients with this condition had a pre-existing liver disease and 11 died of endotoxic shock.
The second type of clinical presentation was wound infections that occurred after individuals
were either exposed to seawater or who injured their hands while handling crabs. None of the
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people with wound infections had any pre-existing liver diseases. Interestingly, Blake et al.
noticed that of the infections, most occurred during the warmer months (85%), most were men
(90%), and 95% of the infections occurred in individuals over the age of 40. A more extensive
study was performed by Hlady and Klontz (23) showed that three distinct clinical presentations
were possible. Patients suffering from gastroenteritis from a V. vulnificus infection presented
with diarrhea, abdominal cramping, nausea, fever, and vomiting. The average patient recovered
in 8.1 days. Other patients presenting with wound infections experienced fever and cellulitis.
Only individuals who were dockworkers, fisherman, or oyster shuckers presented with wound
infections and on average, they recovered in 8.3 days. Individuals suffering from the most severe
form of infection, primary septicemia, presented with fever, diarrhea, nausea, abdominal
cramping, vomiting, and swollen painful lower extremities with hemorrhagic bullae. Of those
presenting with V. vulnificus infections, most were male, and fatality rates were 6% for
gastroenteritis, 11.3% for wound infections and 56% for primary septicemia.
In a study from 1988-1996, Shapiro et al. (43) demonstrated that liver disease was a
strong predictor of a fatal outcome of V. vulnificus infections. Of the 113 patients who had
hepatic disease in this study, 58% suffered from cirrhosis, 24% hepatitis, 16% cirrhosis and
hepatitis, 1% metastatic cancer, and the remaining 1% had a liver transplant. In addition to
hepatic disease, individuals with hematologic diseases such as anemia, thrombocytopenia,
leukemia, thalassemia major and minor, and hemochromatossis; and immuno-compromised
individuals (HIV, splenectomy, chemotherapy, steroid treatment) were also predisposed to septic
infections by V. vulnificus.
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The Economic Problem
Today, shellfish are commercially harvested from the waters of the Atlantic, Pacific, and
Gulf coasts with over 22 coastal states harvesting shellfish from their waters. In 1995, the FDA
estimated that there were approximately 100,000 shellfish illnesses which cost approximately
$201.9 million dollars. Vibrio vulnificus was estimated to be responsible for 60% of shellfish
diseases. Many of the estimated 60,000 V. vulnificus infections were probably gastroenteritis
which the FDA admitted went largely unreported. According to the FDA, the cost of V.
vulnificus is approximately $120 million dollars annually due to the high mortality rate
associated with the bacterium. Although V. vulnificus is widely accepted as being the major
cause of shellfish disease, in 1995, there were only 32 confirmed cases of V. vulnificus with 14
deaths (44). This suggests that the FDA may have overestimated the impact of V. vulnificus. In
1999, 165 million pounds of shellfish were processed (oysters: 26 million, scallops: 26 million,
clams: 111 million, and mussels: 2 million) (44). According to the National Marine Fisheries
Service Office of Science and Technology Fisheries Statistics Division, the annual person
consumes 16.3 lbs of seafood each year and approximately 0.1% of that is ingested raw. The fact
that V. vulnificus is a health problem for some individuals, coupled with repeated warnings about
the risks of shellfish consumption (45, 46) has led to a 60 percent decrease in the consumption of
oysters over the past decade (47).
Fear of acquiring V. vulnificus from seafood has caused a devastating impact on the
seafood industry, particularly in Florida, Alabama, Texas, and Louisiana which rely heavily upon
the oyster industry (43, 47). In order to inform the public about the risk associated with V.
vulnificus, California, Florida, and Louisiana each require notices to be posted at sites that retail
raw oysters (46). In order to protect the community at large, researchers have been developing

6

tests to 1) rapidly identify V. vulnificus in food before contaminated meat reaches consumers,
and 2) sub-type V. vulnificus isolates to determine if a particular variant of the bacterium is more
likely to cause clinical disease than others.
Identification Systems
One of the first steps in identifying V. vulnificus in either the environment or seafood is to
identify its presence. In order to accomplish this, many types of selective media have been
developed that select for the genus Vibrio and differentiate many of the species such as cholerae,
vulnificus, and parahaemolyticus. The first widely used selective media was thiosulphate citrate
bile salts sucrose (TCBS) (48). This medium utilized an alkaline pH (8.6) along with ox bile and
1% NaCl as selective ingredients for the genus Vibrio. The main problem with the utilization of
this medium was that only 51% of the bacteria isolated with it actually belonged to the genus
Vibrio (49). The first medium developed to selectively isolate V. vulnificus was sodium dodecyl
sulfate-polymyxin B-sucrose agar (SPS) (50). This medium differentiated between V.
parahaemolyticus and V. vulnificus using the fermentation of sucrose and the enzyme sulfatase.
Vibrio vulnificus would produce a halo around a blue colony where as V. parahaemolyticus
would not. As with TCBS, SPS had varying plating efficiencies for V. vulnificus ranging from 11
to 74% (51) resulting in the need for a better selective medium.
In 1987, Massad and Oliver (52) created what would become the gold standard for V.
vulnificus media. Cellobiose polymyxin B colistin agar (CPC) was unique in that it used the
antibiotics colistin and polymyxin B as selective agents. The differential agent in the media was
the fermentable carbohydrate cellobiose. On this medium V. cholerae produce purple colonies
and V. vulnificus produced yellow colonies with a yellow halo, while other strains of Vibrio were
unable to grow except for one isolate of V. parahaemolyticus. Modified CPC or mCPC was
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described in 1991 by Tamplin et al. (53) as an alternative to CPC for increased recovery of
environmental samples. This new medium used the same formula as CPC except that the colistin
concentration was reduced three and a half fold. Several experiments validated the effectiveness
of V. vulnificus detection on mCPC as being 95% accurate (34, 54). While other media [V.
vulnificus agar (54), V. vulnificus enumeration medium (55), V. vulnificus medium (56),
cellobiose colistin medium (57), and peptone, NaCl, cellobiose, and colistin medium (58)] have
been used in the isolation of V. vulnificus, CPC and mCPC are still the most commonly used
media for the recovery of V. vulnificus from the environment.
Once a putative V. vulnificus, has been isolated on selective media, a number of assays
can be used to confirm the presence of this species. The most basic of all the assays is simple
biochemical analysis of isolates as recommended in the FDA’s Bacteriological Analytical
Manual Online chapter on Vibrio (59).
Immunologic methods of detection have been used for the confirmation of V. vulnificus
as well. Originally, a heat-stable intracellular protein was used in a diffusion assay to detect V.
vulnificus (60). Years later, Tamplin et al. (53) developed a monoclonal antibody (MAb)
designated FRBT37 for use in an enzyme immunoassay that was approved by the FDA to be
used as a detection tool. While biochemical and immunologic assays are reliable in the detection
of V. vulnificus they require pure cultures of V. vulnificus. In addition, these techniques also rely
on culturable bacteria. Vibrio vulnificus has been shown to enter a VBNC (28), where the cells
are nonculturable and consequently biochemical and immunologic assays cannot be used to
confirm the presence of the bacterium.
As a means of getting around the need to culture V. vulnificus from the environment, two
methods utilizing molecular assays have been developed to account for V. vulnificus in the
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VBNC state. The Southern blot utilized DNA probes against the V. vulnificus cytolysin gene
(vvhA) to confirm the presence of V. vulnificus in both clinical and environmental isolates (54,
55, 61, 62). Polymerase chain reaction (PCR) analysis has also been used to confirm the presence
of V. vulnificus. The original PCR reactions targeted the vvhA gene (63, 64) and were capable of
detecting V. vulnificus in oyster tissue and bacteria in the VBNC. The limit of detection in the
above assays were 31 ng of DNA from VBNC and 72 pg (or approximately 103 cells) of DNA
from culturable cells (63) and 102 CFU/g of oyster meat (64). Other PCR methods have been
reported with the multiplex and real-time PCR assays providing the most immediate and reliable
method of V. vulnificus detection. In 2004, Panicker et al. developed both a multiplex PCR assay
(65) and a real-time assay (66) for V. vulnificus detection. Vibrio vulnificus levels as low as 102
to 103 CFU/g of oyster meat could be detected with both multiplex and real-time PCR.
Enrichment for 5 hours lowered the detection limits of both tests to approximately one colony
forming unit per gram of oyster tissue.
Sub-Typing Systems
To effectively track V. vulnificus variants for epidemiological studies, many different
methods have been employed in order to sub-type V. vulnificus. The most basic sub-typing
technique is biotyping. Utilizing biochemical profiles of organisms has allowed researchers to
place V. vulnificus into three different biovars. Biotype 1 and 2 organisms were defined by Tison
et al. in 1982 (38) based on their ability to produce indole, ornithine decarboxylase (ODC), and
grow at 42ºC, with biotype 1 being positive for the aforementioned assays. In 1996, Amaro and
Biosca (67) also demonstrated that biotype 1 and 2 were both pathogenic for mice, while biotype
2 was also capable of causing disease in eels. Biotype 3 was described as being a hybrid of
biotypes 1 and 2 but is differentiated from biotypes 1 and 2 based on positive reactions for
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indole, ODC, and negative reactions to lactose, cellobiose, citrate, and salicin (19, 68). As of this
time, biotype 3 organisms have only been reported in Israel (19).
Another method of sub-typing V. vulnificus uses capsule production as defined by colony
morphotype appearances. Kreger and colleagues (69, 70), described an extracellular acidic
polysaccharide expressed by virulent V. vulnificus cells that impedes phagocytosis by host cells.
Amako et al. (71) and Yoshida et al. (72) each were able to demonstrate that capsules allowed
cells to be serum resistant, resist phagocytic activity, and increase tissue invasiveness.
Furthermore, colony morphotypes that were opaque were defined as the virulent, capsule
producing isolates whereas translucent colonies were defined as acapsular and avirulent (71-73).
Recently, Grau et al. (74), described a new colony variant, rugose, whose colony phenotype
appeared as dry and wrinkly on solid agar. The rugose variant appeared to be a capsular mutant,
but interestingly, was present in both opaque and translucent varieties of V. vulnificus. Virulence
of the rugose morphotype was associated with opacity; the opaque form was virulent while the
translucent form was avirulent in the mouse model (75). Different levels of colony opacity have
been described in V. cholerae (76). Rosche et al. (77) recently described an intermediate colony
phenotype in V. vulnificus. While V. vulnificus has been shown to switch colony morphotypes
from opaque to translucent (72, 78, 79), the intermediate colony phenotype was stable and is the
first published evidence of a stable alternate phenotype aside from those generated by Grau (75).
Virulence studies related to the intermediate colony phenotype have not been reported.
Like other Gram-negative bacteria, Vibrio vulnificus has three major cell surface
antigens (Ag): capsule (K antigen), flagella (H antigen), and lipopolysaccharide (LPS) (O
antigen). Of these, only flagella are composed of protein. Unfortunately, the antigenic
determinant on the flagella is conserved amongst all groups of V. vulnificus (80) and is not useful

10

for typing strains. While the LPS is the component responsible for endotoxic shock (81), the
capsule is essential for evasion of host resistance mechanisms. Although the capsule of V.
vulnificus was poorly immunogenic (82), polyclonal antibodies were generated that reacted with
clinical and environmental isolates demonstrating that several capsular serotypes exist (12, 82).
The capsular typing system is based on polyclonal antibodies; however, one MAb was generated
against a type 1 capsule of V. vulnificus but it has never been used in any typing system (83).
Two LPS-based antibody typing systems are currently available. The first system is a
polyclonal antibody-based system that recognizes LPS strains that are either virulent (E serotype)
or avirulent (A serotype) for eels (84, 85). The second, is a LPS MAb-based typing system
developed by Martin and Siebeling (86) that was able to sub-type over 56% of the isolates
examined in their study into one of five LPS serotypes. Based on their work and the polyclonal
antibody data from Shimada and Sakazaki (87), they proposed that there should be two
remaining serovars for which typing reagents had yet to be identified. Zuppardo et al. (88), used
the LPS typing system of Martin and Siebeling (86) to analyze clinical, environmental, and
oyster retail isolates. The LPS serovar O1 used in this study was previously referred to as serovar
O3 by Martin and Siebeling (86). Zuppardo et al. (88) were able to type 61% of clinical isolates,
41% of environmental isolates, and 44% of retail isolates, showing that there were other LPS
serovars that were yet to be identified. Interestingly, they were unable to type any isolates as
either O1 or O5, but rather they found an O1/O5 serovar. With the exception of Amaro’s
serogroup E (67, 85, 89), none of the serotyping methods available were able to correlate a
particular capsule type, or LPS type with virulence.
In an effort to correlate a typing system with virulence, molecular methods including
ribotyping, genotyping, and PCR typing have been employed. Ribotyping, which is PCR
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amplification of 16S and 23S rRNA and subsequent digestion with Hind III, has been successful
in grouping isolates into 1 of 36 clusters (90). Subsequent analysis of previously ribotyped
organisms has shown that ribotypes are very stable (90, 91). While no individual cluster has been
associated with virulent versus avirulent strains, Hoi et al. (12) were able to use ribotyping to
show a correlation between geographical location and ribotypes. Pulsed-Field Gel
Electrophoresis (PFGE), a more discriminatory method than ribotyping, uses restriction patterns
of genomic DNA generated by cutting with low-frequency restriction enzymes to discriminate V.
vulnificus isolates. Tamplin et al. (92) demonstrated high-level variation in restriction length
polymorphism profiles among 53 clinical and 78 environmental isolates contradicting the higher
levels of similarity generated by ribotyping. Pulsed-Field Gel Electrophoresis has been used to
determine that as many as 100 different genotypes of V. vulnificus may be present in a single
oyster (93). Jackson et al. (94) demonstrated the power of PFGE by showing both the number of
V. vulnificus variants present in an oyster and that the isolate recovered in the patient’s blood
sample matched only one of the genotypes present in the oyster meat. While the technique of
PFGE is very powerful, it is very time consuming and would require the generation of an
extensive database for the identification and comparison of virulent and avirulent strains.
Two studies utilizing PCR have demonstrated much promise in predicting strain
virulence in V. vulnificus. In 2003, Nilsson et al. (95), demonstrated that a sequence
polymorphism of the 16S rRNA gene was a possible indicator of strain virulence. The
polymorphisms in the 16S rRNA genes were defined as type A and B. In their study 26 of the 34
isolates originating from a clinical setting were classified as type B while 31 of 33 environmental
isolates belonged to type A. Interestingly, 17 of the 18 isolates from clinical fatalities belonged
to rRNA type B while only 2 of the 33 environmental isolates were type B. This study
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demonstrated a possible association between the type B 16S rRNA allele and the potential
virulence of a given V. vulnificus strain. In a separate experiment, Rosche et al. (96)
demonstrated that differences in the sequence of the vvhA gene could be exploited in randomly
amplified polymorphic DNA (RAPD) PCR to group V. vulnificus into two separate groups (Ctype and E-type). It is of interest to note that 72% of their clinical isolates typed as C-types and
93% of their environmental isolates were E-types. Because 28% of their clinical isolates typed as
E-types, they proposed that E-types are potentially virulent, but less likely to cause disease. Eight
strains were assayed by both methods with four isolates belonging to the 16S rRNA group B and
C-type and the other four belonging to the 16S rRNA group A and E-type, showing agreement
between the two typing systems.
A recent study by Chatzidaki-Livanis et al. (97) attempted to correlate the findings of
Nilsson et al. (95), Chatzidaki-Livanis et al. (98), and Rosche et al. (96) by comparing 16S
rRNA types A and B with CPS alleles 1 and 2 with E-types and C-types along with a repetitive
extragenic palindromic DNA PCR (rep-PCR). Seven distinct rep-PCR genogroups were
identified with the majority of clinical isolates (61%) belonging to genogroups I, IV, and VII,
and 94% of the oyster isolates belonged to genogroups II, and III. In general, rep-PCR was in
general agreement with the other multilocus genotype profile distributions but provided more
discrimination for tracking genetic differences in clinical and environmental isolates. The repPCR technique provides rapid and sensitive monitoring of clinical and environmental
populations, but as with other studies, it does not provide a definitive correlation between
virulent and avirulent strains.
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Present Studies
As stated above, there are numerous biochemical, immunologic and molecular methods
for typing V. vulnificus strains and each has its advantages and problems. The purpose of these
studies was to continued the work of Martin and Siebeling (86), and improve the typing system
by generating and characterizing additional reagents. Based on the work of Martin and Siebeling
(86), two clinical isolates, strains 1003 and 1008, were used to generate new reagents since
Martin and Siebeling suggested these strains might be representative of the remaining two
serovars. In the work presented here, MAbs were generated to LPS from strains 1003 and 1008.
The two new LPS serovars, previously unidentified by Martin and Siebeling (86), were
characterized as to their distribution in clinical and environmental isolates using a panel of 154
strains of V. vulnificus provided by scientists in the United States and Europe. This expansion of
the previous LPS typing system added to the number of isolates that can now be typed. As an
alternative to traditional MAbs, the heavy and light chain variable region sequences from one of
the resulting hybridomas, RS1, were express in a phage-displayed antibody (PDAb) system.
Lastly, the MAbs generated in this study were used in conjunction with those generated by
Martin and Siebeling (86) to examine the proposed association of capsule and LPS variation and
test the hypothesis that decreased capsule production is associated with changes in LPS
phenotype.
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CHAPTER 2:
PRODUCTION OF MONOCLONAL ANTIBODIES TO
SEROVARS O6 AND O7
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Introduction
Infections caused by V. vulnificus have been reported in most parts of the world (4, 12,
15, 18-20, 67). Environmental studies in the United States have shown that V. vulnificus can be
found in virtually all coastal areas during the warmer months of the year (13, 20, 26, 99-102).
Although it is unknown what the lethal dosage is for humans, it has been shown that certain
people are naturally pre-disposed to infection. People who are most susceptible to infection
usually suffer from chronic diseases of the liver or immune system (103). Due to the widespread
distribution of V. vulnificus and its virulence towards humans with predisposing conditions, it is
important to develop methods for reliable detection and epidemiologic tracking of this
microorganism in both clinical and environmental samples. Methods for the differentiation of
strains are more complex. A number of methods have been used including biotyping (19, 38, 67,
104-106), serotyping (82, 86, 87, 89), and molecular typing (16, 88, 90-92, 94-96, 107-109).
Historically, V. vulnificus infections have been designated as either clinical or
environmental isolates. The clinical designation belongs to any organism isolated from a human
patient in a hospital setting and the environmental designation is given to an organism isolated
from any environmental source. Although V. vulnificus can infect oysters, fish, shrimp, and eels
(12, 15, 16, 19, 26, 38, 53, 110), the isolate is given an environmental classification regardless as
to whether or not the isolate is capable of causing the host disease.
In V. vulnificus, three distinct biotypes exist based on select biochemical reactions.
Biotype 1 isolates are indole positive, ODC positive, grow at 42°C, and are pathogens for
humans and biotype 2 isolates are generally negative for the above reactions, are eel pathogens,
and may or may not cause disease in humans (38). Biotype 3 seems to behave as a hybrid of
biotypes 1 and 2. They are indole positive, ornithine decarboxylase positive, but growth at 42ºC
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is unreported as of this time (19). In addition, biotype 3 strains are lactose, cellobiose, citrate,
and salicin negative while biotypes 1 and 2 are positive for the later four tests (19, 68).
Shimada and Sakazaki (87) described a serotyping system based on direct agglutination
of heat-killed V. vulnificus with polyclonal antisera raised in rabbits. Since heat-killed V.
vulnificus was used as the antigen in the agglutination assay, it was assumed that the heat-labile
H-antigen had been destroyed and that any visible reaction that was taken place was between the
antisera and the bacterial cell wall associated antigens. Using this assay, Shimada and Sakazaki
proposed that V. vulnificus had seven serovars. Martin and Siebeling (86) developed a MAbbased LPS (O-antigen) serotyping system against five distinct serovars utilizing isolates of V.
vulnificus obtained from the Louisiana Department of Health and Human Resources (LDHHR).
These five MAbs could be correlated to five of the serovars proposed by Shimada and Sakazaki.
Martin and Siebeling’s serotyping system (86) was based on LPS and was the first typing
system for V. vulnificus that was based on a virulence factor. Zuppardo et al. (88) compared
epidemiological data for oysters from the Gulf of Mexico and the Atlantic coast and examined
their correlation with human disease. Zuppardo et al. (88) reported no significant difference
between the LPS serotype patterns of V. vulnificus isolated in either the Gulf of Mexico or the
Atlantic Ocean with regards to serovars O2, O3 and O4; however, serovars O1/O5 occurred
solely in Gulf of Mexico isolates as proposed by Siebeling (111).
The aim of this study was to define the distribution patterns of LPS serovars in the
artificial clinical vs. environmental classification scheme, as well as the more natural
classification of biotyping. In order to accomplish this, I generated two additional MAbs to
isolates 1003 (O), and 1008 (O) and used these in combination with the original five LPS
specific MAbs identified by Martin and Siebeling (86). The combination of the newly developed

17

MAbs in conjunction with Martin and Siebeling’s MAbs allowed me to have a more complete
epidemiologic picture of the distribution patterns of V. vulnificus on both a global and regional
scale.
Materials and Methods
Bacterial Strains. All isolates of V. vulnificus were provided by the LDHHR, the Centers for
Disease Control and Prevention, Angelo DePaola at the United States Food and Drug
Administration Laboratory at Dauphin Island, AL, and personal collections of Carmen Amaro
(University of Valencia, Valencia, Spain), Todd Cassanova (Our Lady of the Lake Hospital,
Baton Rouge, LA) Paul Gulig (University of Florida, Gainesville, FL), John Hawke and Ron
Thune (Louisiana State University School of Veterinary Medicine, Department of
Pathobiological Sciences, Baton Rouge, LA), Marlene Janes (Louisiana State University,
Department of Food Science), and Ronald Siebeling (Louisiana State University, Department of
Biological Sciences) (Table A.1). The Vibrio cholerae O139, Salmonella arizonae, Serratia
marscensens, S. enteritidis, Citrobacter freundii, and S. typhimurium isolates were from the
collection of Ronald Siebeling. Vibrio parahaemolyticus was obtained from Marlene Janes,
Deinococcus radiodurans was obtained from John Battista (Louisiana State University,
Department of Biological Sciences) and the Vibrio fluvialis was from Todd Cassanova (Table
A.1). All bacteria were cultured on heart infusion (HI) agar or broth as appropriate. For Vibrio
spp., the final salt concentration was raised to 0.34 M.
Heat-killed bacteria were used in some immunizations and were prepared according to
the method of Sakazaki et al. (112). Briefly, V. vulnificus 1003 (O) and 1008 (O) were grown
overnight in HI broth containing 0.34 M NaCl at 37°C with shaking. Cultures were heated to
100°C in a water bath for 2 hours. Cultures were then centrifuged at 10,000 x g for 10 min to
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pellet the cells. The cells were then resuspended in 0.15 M NaCl and centrifuged at 10,000 x g
for 10 min again. The supernatant was discarded and cell pellets were blotted on a paper towel
for 10 min. Total protein was estimated from the weight of the wet cells using the following
equation: total protein = 0.075 x wet weight of cells. The cells were then resuspended in 0.15 M
NaCl to a concentration of 1 mg of total protein/ml. Fresh heat-killed whole cell antigen was
prepared for each immunization.
Purification of LPS. Vibrio vulnificus was grown on heart infusion (HI) agar and incubated at
30°C overnight to confluent lawns. Agar was washed four times with 10 ml of 0.15 M NaCl to
harvest the cells and the LPS was extracted using the hot water/phenol extraction method (113).
Purified LPS was stored either lyophilized at room temperature or dissolved in deionized water
(dH2O) at a concentration of 1 mg of LPS/ml.
In some cases, LPS was enriched using the method of Hitchcock and Brown (114) with
modifications by Amaro et al. (115). Briefly, overnight V. vulnificus cultures grown in HI broth
at 37°C overnight and diluted in phosphate buffered saline (PBS) to an optical density of 0.8 at
600 nm. One and a half milliliters of diluted cultures was centrifuged at 16,000 x g for 5 min at
room temperature. The cell pellet was resuspended in 10 µl of PBS and 50 µl of electrophoresis
sample buffer [0.0625 M Tris, 10% (v/v) glycerol, 5% (v/v) 2-Mercaptoethanol, and 0.008 M
lauryl sulfate (SDS), pH 6.8] was added and the cells were boiled for 10 minutes. Fifty
micrograms of proteinase K (Sigma Chemical Co., St. Louis, MO) in 10 µl of electrophoresis
sample buffer was added to each sample, and the mixture was incubated for 60 min at 60°C. The
proteinase K digested, LPS containing extracts were stored at -20°C until use.
Analysis of LPS on SDS-PAGE. Hot water/phenol extracted LPS samples were separated on a
12.5% SDS-PAGE gel with a 4% stacking gel. Samples were electrophoresed at 100 V until
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samples entered the separating gel at which time they were electrophoresed at 150 V until the
running dye reached the bottom of the gel. Gels were stained using the Bio Rad (Hercules, CA)
Silver Stain Plus kit. Hot-water/phenol purified LPS from Salmonella typhimurium (Sigma
Chemical Co.) was included as a positive control for silver staining.
Vibrio vulnificus Western Blot Analysis. Whole-cell lysates, proteinase K digested whole-cell
extracts, and hot water/phenol extracted LPS were separated with SDS-PAGE as described
above except the gels were run at 200 V until the running dye reached the bottom of the gel.
Samples were transferred on to Protran nitrocellulose membranes (Schleicher and Schuell,
Keene, NH) by blotting for 90 min at 90 V. Blots were blocked overnight at 4ºC in 10%
powdered milk in NET (0.05 M Tris, 0.001 M EDTA, 0.15 M NaCl, pH 7.4). Blots were then
washed multiple times with NET over the next 30 min. Antibodies were diluted in NET
containing 10% powdered milk (polyclonal 1:1000 and monoclonal 1:2), added to blots and
incubated for 1 h at room temperature. Blots were again washed 4 times with NET. A
horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) (Jackson ImmunoResearch
Laboratories Inc., West Grove, PA), diluted 1:5000 in NET containing 10% powdered milk, was
added to the blots and incubated for 1 h at room temperature. Blots were washed 4 times with
NET, and 3, 3’, 5, 5’ tetramethylbenzidine (TMB) Microwell Peroxidase Substrate (1Component) Sureblue™ (Kirkegaard & Perry Laboratories, Gaithersburg, MD) and TMB
Membrane Enhancer (Kirkegaard & Perry Laboratories) was added. Blots were incubated at
room temperature and the reaction was terminated by placing the blots in dH2O.
Immunization of Mice. BALB/c mice were obtained from the breeding colony maintained at the
Louisiana State University School of Veterinary Medicine, Division of Laboratory Animal
Medicine. Female BALB/c between 6 to 8 weeks of age were used for this study. Mice were
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immunized with 200 µg of total protein from the appropriate strain of heat-killed V. vulnificus in
0.15 M NaCl (200 µg/ 200 µl) on day 0 via an intraperitoneal (ip) injection. Mice were boostered
on days 14 and 21, followed by an ip injection of purified LPS in 0.15 M NaCl (50 µg/200 µl) on
day 28. Mice were bled for serum on the day of immunization and the antibody titer for V.
vulnificus LPS was determined by ELISA as described below. A titer of ≥ 2000 was deemed
acceptable. If titers were low, mice were boostered with LPS at two week intervals until
acceptable titers were obtained.
Generation and Characterization of MAbs. P3-X63-Ag8.653 (116) myeloma cells were used
as a fusion partner and maintained in RPMI-1640 culture medium (Sigma Chemical Co.)
supplemented with NaHCO3, 25 mM HEPES, GlutaMAX™-1 (2 mM) (Gibco, Grand Island,
NY), penicillin (10 U)/streptomycin (0.1 mg) (Sigma Chemical Co.), MEM non-essential amino
acid solution (Sigma Chemical Co.), nystatin (10 U/ml) (Sigma Chemical Co.), and 20% fetal
bovine serum (FBS) (Hyclone, Logan, UT) (culture medium). Myeloma cell cultures were split
1:2 daily for 3 days prior to fusion. Splenocytes were harvested from immunized mice 3 days
after the final immunization. Fusions were performed as previously described (117) with the
following modifications. In the fusions, the cell ratio of myelomas to splenocytes ranged
anywhere from 10:1 to 4:1. Cells from each fusion were suspended in 50 ml of culture medium
and evenly distributed among 5, 96-well flat-bottom cell-culture plates seeded with peritoneal
exudate cells. Peritoneal exudate cells (PECs) were harvested from two, 10 to 12 week old
female BALB/c mice as previously described (117) except that pooled PECs were centrifuged at
200 x g for 10 min at 4°C, resuspended in 50 ml of culture medium and plated in 96 well plates.
Peritoneal exudate cells were incubated 16 to 24 hours at 37°C with 5% CO2 prior to addition of
hybridoma cells.
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On or around day 17, cell culture supernatant from each well was tested for the presence
of anti-V. vulnificus antibodies by either a whole-cell or LPS enzyme-linked immunosorbent
assay (ELISA) described below. Hybridoma wells producing antibody of interest were cloned by
a limiting dilution as previously described (117) with the following modifications. All
hybridomas wells of interest were diluted in culture medium. Cells were plated on PEC-seeded
96 well plates such that 32 wells received 10 cells/well, 32 wells received 1 cell/well, and 32
wells received 0.1 cells/well. The plates were then incubated at 37°C with 5% CO2 for 7 to 10
days at which time the plate was scored by using an inverted microscope to identify monoclonal
wells. Monoclonal wells were further screened by either whole-cell ELISA or LPS ELISA.
Those wells testing positive were then expanded. The parent hybridoma and up to six clones
were cryopreserved. The isotype of each MAb was determined using the FisherBiotech SBA
Clonotyping System II kit (Fisher Scientific, Houston, TX) using whole-cell antigen.
ELISAs. Three variations of ELISA were used in this study. The ELISA procedure used to
identify anti-V. vulnificus antibody producing clones was modified from the whole cell ELISA
procedure described by Martin and Siebeling (86). Antigen plates were prepared on Immulon IV
ELISA plates (Dynatek Laboratories, Chantilly, VA) as previously described. Plates were used
immediately or stored at -20°C for up to 6 months. To measure murine antibodies, plates were
allowed to reach room temperature and each well was washed once with NET containing 0.05%
Tween-20 (NET-T). Wells were blocked for 1 hour at 37°C with 200 µl of PBS with 2% fish
gelatin (Sigma Chemical Co.) (blocker). Plates were washed 3 times with NET-T and 50 µl of
serially diluted immunized mouse serum or hybridoma supernatant diluted 1:2 in blocker with
0.05% NaN3 was added to each well. Phosphate buffered saline or culture medium was used as a
blank where appropriate. Plates were incubated for 1 h at 37°C then washed 5 times with NET-T.
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The secondary antibody, goat anti-mouse IgG (H+L) horseradish peroxidase-conjugate (Jackson
ImmunoResearch Laboratories Inc.) was diluted 1:2000 in blocker, and 50 µl of this antibody
was added to each well followed by incubation at 37°C for 1 h. The plates were washed 5 times
with NET-T and blotted dry. Then 100 µl of Sureblue™ TMB substrate (Kirkegaard & Perry
Laboratories) was added to each well. The reaction was allowed to develop for up to 10 minutes
at room temperature and stopped by addition of 0.1 N H2SO4. The absorbance at 450 nm was
determined on a MRX Revelation Microplate Reader (Dynex Technologies, Chantilly, VA). A
positive reaction was defined as an OD450 value ≥ two times the negative control plus 0.1.
Monoclonal antibody containing supernatants were further characterized using purified
LPS as antigen in a procedure modified from that described above. Briefly, 50 µl of purified LPS
diluted in PBS to a concentration of 1 mg/ml in PBS was added to each well of an Immulon I
ELISA plate (Dynatech Laboratories), and the plate was incubated overnight at 37°C in order to
dehydrate each well. The ELISA plates were removed from the incubator the next day and either
used immediately or stored at -20°C. When using LPS as the antigen, the concentration of NaCl
in the wash buffer was raised from 0.15M to 0.25 M (high-salt NET).
For serotyping of the bacterial strains, each V. vulnificus isolate was grown overnight in
HI broth containing 0.34 M NaCl. Cells were diluted in an equal volume of PBS yielding
approximately 108 cells/ml and plated at 100 µl per well on an Immulon IV ELISA plate. The
ELISA was performed as described above. Seven MAbs were used for each strain; five of these,
SM1 (anti-O1/O5), SM4 (anti O2), SM11 (anti- O3), SM31 (anti-O4), SM46 (anti-O1/O5), had
been previously reported (15). Two, RS1 (anti-O6) and RS2 (anti-O7) were generated as part of
this study (Table A2).
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Biotyping. Many of the bacterial isolates used in this study had not been biotyped. If the biotype
of a strain was undetermined, it was classified as biotype 1 if it grew at 42°C, produced indole
and ODC. If it did not have these characteristics it was defined as biotype 2. The ODC assay and
indole production assays were performed as previously described (118) except all medium
contained 0.34 M NaCl. The 42°C growth assay was performed by streaking overnight broth
cultures on slants and incubating the slants overnight in a 42°C water bath.
Immuno-Electron Microscopy. Vibrio vulnificus isolates 1003 (O) and 1008 (O) were grown
overnight at 37°C in HI broth containing 0.34 M NaCl. Bacterial cells were incubated on a 400
copper mesh, transmission electron microscope (TEM) grid coated with carbon film (Electron
Microscopy Sciences, Hatfield, PA) for 5 min at room temperature. Next, the grid was incubated
with 20 µl of MAb for 15 min at room temperature. The grid was then washed two times in PBS
and a third time in ddH2O. The grid was then treated with 18 nm colloidal gold-labeled goat antimouse IgM and IgG (H+L) antibody (Jackson ImmunoResearch Laboratories, Inc.) diluted 1:50
in PBS and again washed two times with PBS and a final wash with ddH2O. Cells were observed
on a JEOL Model 100CX TEM.
Statistical Analysis. The Kruskal-Wallis test was used for the comparison of LPS serovar
distribution between the different classification schemes. Comparisons with a P value of less
than or equal to 0.05 were considered statistically significant.
Results
Analysis of LPS. Hot water/phenol extracted LPS of V. vulnificus were examined on a silver
stained SDS-PAGE gel (Fig. 2.1). Purified LPS from each isolate produced two low molecular
weight bands, with the exception of V. vulnificus 1007 (O) which only produced one band, and
no high molecular weight bands indicative of smooth LPS. Although the lack of high molecular
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FIG. 2.1. Silver stained Vibrio vulnificus LPS SDS-PAGE gel. Lanes 1-7 contained 5 µg of hot
water/phenol extracted LPS from V. vulnificus 1001, 1003, 1004, 1005, 1007, 1008, and 1009
respectively. Note no high molecular weight LPS bands indicative of smooth LPS. Lanes 8 and 9
contained 5 and 10 µg of hot water/phenol purified LPS from Salmonella typhimurium,
respectively.
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weight bands is uncommon in Gram-negative organisms, V. vulnificus has only been shown to
possess high molecular weight bands through immunoblots of biotype 2 organisms (115).
Identification of New Serovars. Monoclonal antibodies were developed against V. vulnificus
isolates 1003 (O) and 1008 (O), the two isolates that were not detectable by any of the MAbs in
the LPS typing system of Martin and Siebeling (86). Hybridomas of interest (RS1 and RS2) were
identified by whole-cell and LPS ELISA and tested against other identified serovars of V.
vulnificus as well as numerous heterologous bacterial species. Figure 2.2 shows each MAb used
in this study and their capacity to bind one LPS serotype selectively. In their original paper,
Martin and Siebeling (86) developed MAbs to serovars O1-O5. While they were able to
distinguish serovars O1 and O5 with SM1 and SM46, I was unable to show that SM1 recognized
serovar O1 exclusively, nor was I able to show that SM46 recognized O5 exclusively. Rather,
what I noticed was that all isolates that were recognized by the MAb SM1 were also recognized
by SM46. This led me to designate bacteria that were previously classified as LPS serotype O1
or O5 as a hybrid LPS serotype designated O1/O5. This pattern was seen in other studies as well
(88). All other MAbs, SM4, SM11, SM31, and SM46 reacted as previously described (86). The
MAbs, RS1 and RS2, bound to their immunizing strains, 1003 (O) and 1008 (O), respectively,
but not to the other typing strains used by Martin and Siebeling (86). Figure 2.2 shows that both
RS1 and RS2 have no cross-reactivity with serovars O1-O5 and bind selectively to previously
unidentified isolates. RS1 and RS2 identify the designated serovars O6 and O7, respectively.
Western Blot Analysis of LPS. Polyclonal antibodies against V. vulnificus whole-cells and
newly developed MAbs, RS1 and RS2, were reacted with whole-cell lysates, proteinase K
digested whole-cell lysates, and hot water/phenol extracted LPS to determine their ability to
produce a LPS ladder for V. vulnificus as previously described (115). Figure 2.3 shows that
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FIG. 2.2. Optical density values for seven monoclonal antibodies generated against Vibrio
vulnificus. Each MAb is specific for a single serotype with the exception of SM1 and SM46
which both recognize serotype O1 and O5. The newly developed RS1 and RS2 monoclonals
recognize serotypes O6 and O7. Sample sizes are presented but differ for monoclonal antibody
RS2. HBS= heterologous bacterial species.
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FIG. 2.3. Polyclonal western blot analysis of Vibrio vulnificus. Lane1 contained 10 µl of V.
vulnificus whole-cell lysate and lane 2 contained 10 µl of whole-cell lysate that had been
digested by proteinase K. Lane 3 had 5 µg of hot water/phenol extracted V. vulnificus LPS. The
presence of bands only in lane 1 indicated that the polyclonal antibodies were binding protein
and not polysaccharides. This blot was indicative of all the 1000 series of V. vulnificus isolates
used in this study.
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polyclonal antibodies were capable of labeling bands in the V. vulnificus whole-cell lysates.
Whole-cell lysates that had been digested with proteinase K did not have any bands, indicating
that the bands in the whole cell lysates were probably protein and not polysaccharide in structure.
There was no evidence of the polyclonal antibodies reacting with purified LPS from any of the
V. vulnificus isolates. Monoclonal antibodies RS1 and RS2 were used in western blot analysis as
well, but as in the polyclonal western blot analysis, there was no binding of antibodies to any of
the purified LPS from the V. vulnificus isolates.
Electron Microscopy of RS1 and RS2. Monoclonal antibodies RS1 and RS2 were used to stain
bacteria and examined using TEM to determine the cell structure binding. RS1 and RS2 were
visualized by the use of an 18 nm colloidal gold-conjugated anti-IgG antibody. Figure 2.4 panels
A [V. vulnificus 1003 (O)] and C [V. vulnificus 1008 (O)] show cells that were incubated with the
colloidal gold-conjugated antibodies. There was no indication of any specific binding between
the colloidal gold-conjugated antibodies and the bacterial cells. While both RS1 and RS2 MAbs
bound selectively to hot water/phenol extracted LPS, closer examination of panel B and panel D
indicated a difference in the binding characteristics of RS1 and RS2 on whole cells. RS1
appeared to bind in patches to the outer membrane, and RS2 appeared to be evenly distributed
over the surface of the cell. Interestingly, RS1 binds to the outer membrane underneath the
capsular-like material on the outer edge of the cell, whereas RS2 appeared to bind to the outer
edge of the capsular-like material. Neither RS1 nor RS2 showed any affinity for the flagella of
either V. vulnificus 1003 (O) or 1008 (O) as had been reported for V. cholerae-specific anti-LPS
MAb (119).
Biotyping of Vibrio vulnificus Isolates. A panel of over 150 V. vulnificus isolates was collected
from a variety of geographic locations and grouped into 3 different biovars based on their
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FIG. 2.4. Immuno-labeling of Vibrio vulnificus 1003 (O) and 1008 (O). V. vulnificus 1003 (O)
labeled without (A) and with (B) RS1 followed with a colloidal gold-labeled conjugate. Note the
binding of RS1 underneath the capsular material in (B). V. vulnificus 1008 (O) labeled without
(C) and with (D) RS2 followed with a colloidal gold-labeled conjugate. Note the even
distribution of RS2 on the surface of the bacterium. Black bars indicate 1 µm.
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biochemical profiles. For the purpose of this study, biotype 1 organisms were defined as those
isolates that were positive for indole production, produced ODC, and grew at 42°C. If an isolate
was an eel pathogen, it was automatically placed in biotype 2. If eel pathogenicity was unknown,
any isolate that tested negative for indole production, ODC activity, or was unable to grow at
42°C, was classified as a biotype 2 organism. The two biotype 3 isolates used in this study were
previously defined and were not included in the biochemical testing.

The results of the

biochemical assays are shown in Table 2.1. Interestingly, most of the isolates that were classified
as biotype 2 were either negative for ODC or negative for indole production, only one isolate,
CECT 4604, an eel isolate from Spain, was negative for both ODC and indole production. In the
end, there were 112 biotype 1 and 40 biotype 2 isolates.
Lipopolysaccharide Distribution Patterns. Vibrio vulnificus isolates were classified as clinical
or environmental, biotype 1 or biotype 2, and lastly as a United States or European isolate. If an
isolate’s country of origin or clinical status was unknown, it was left out of the analysis for that
particular grouping. All isolates were included in the biotype comparison except for the biotype
3 isolates, Biotype 3/1033 and Biotype 3/12, which were both serovar O3.
The LPS serotype of each isolate was determined using the whole-cell ELISA. Figure 2.2
shows the reactivities of the MAb used in this study. The serovar distribution of the isolates
tested is shown in Table 2.1. The results of the LPS serovar distribution in clinical and
environmental isolates are shown in Figure 2.5. The LPS serovar distribution was slightly
different between the two groups. The clinical isolates had a higher percentage of serovar O1/O5
as compared to the environmental samples, and the environmental group had a higher percentage
of serovars O3 and O4 as compared to the clinical group. Interestingly, 84.6% of the clinical
isolates could be typed by one of the MAbs in the LPS serotyping system whereas a large
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Table 2.1 Biotypes and LPS serotypes of Vibrio vulnificus isolates.
Strain
1456
1674
1466 (O)
1657 (O)
29M
541(Ø)-14C
541(Ø)-2C
541(Ø)-2O
541(Ø)-44C
541(Ø)-57C
541(Ø)-68C
541(Ø)-69C
541(Ø)-7C
90-247
916i
916c
916d
916f
92-271
98-624 DP-C9
99-509 DP-A6
99-540 DP-B6
99-738 DP-B5
ATL-9572
CDC 9070-96
DAL 79040
CDC 9345-95
DAL 6-5000
CECT 529
(ATCC 27562)
CMC-P6
CP Mussel 10 (O)

MLT 124 (O)
MLT 125 (O)
MLT 133 (O)
MLT 198 (T)
CDC 9038-96
LOS 7318
1002 (O)
007 (O)
1013 (O)
1866 (O)
99-581 DP-C7
99-779 DP-D2

Biotype
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

42° C
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

ODC
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Indole
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

LPS Type
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT

1

+

+

+

NT

1

+

+

+

NT

1

+

+

+

NT

1
1
1
1
1
1

+
+
+
+
+
+

+
+
+
+
+
+

+
+
+
+
+
+

NT
NT
NT
NT
NT
NT

1

+

+

+

NT

1
1
1
1
1
1

+
+
+
+
+
+

+
+
+
+
+
+

+
+
+
+
+
+

O1/O5
O1/O5
O1/O5
O1/O5
O1/O5
O1/O5
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Table 2.1 (cont.).
Strain
ATL-9579
ATL-9580
ATL-9824
CDC 9029-95
ORL 8073
CDC 9032-95
ORL 8074
CDC 9047-96
LOS 7506
CDC 9062-96
LOS 7343
CDC 9067-96
DAL 7-9000
CDC 9074-96
ATL 71491
CDC 9076-96
ATL 71504
CDC 9340-95
ORL 8324
CDC 9352-94
ATL 9823
JY 1701
NOL-3727
9058-96
1009 (O)
CDC 9003-97
FLA 9509
1014 (O)
541(Ø)-84C
549 (O)
98-640 DP-E9
98-641 DP-G8
99-584 DP-B12
99-622 DP-E4
99-623 DP-F5
99-645 DP-C4
99-742 DP-A9
99-743 DP-B6
99-780 DP-E1
99-796 DP-E7
CDC 9030-95
ORL 1506
CDC 9031-96
ATL 6-1306
CDC 9075-96
ATL 71503

Biotype
1
1
1

42° C
+
+
+

ODC
+
+
+

Indole
+
+
+

LPS Type
O1/O5
O1/O5
O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1

+

+

+

O1/O5

1
1
1
1
1
1
1
1
1
1
1
1
1

+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+

O2
O2
O2
O2
O2
O2
O2
O2
O2
O2
O2
O2
O2

1

+

+

+

O2

1

+

+

+

O2

1

+

+

+

O2
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Table 2.1 (cont.).
Strain
CDC 9149-95
NSV-5829
CDC 9348-95
NSV 5830
05-130
1005 (O)
541(Ø)-49C
541(Ø)-54C
95-8-6
95-8-6A
98-783 DP-A1
99-537 DP-G7
99-624 DP-C10
C7184 (O)
CDC 9057-96
DAL 8-9131(7)
CDC 9060-96
DAL 7-9002
CDC 9342-95
LOS 6966
CDC9039-96
LOS 7343
JY 1305
LSU 1866
OLOL 1
SRC 10215
89-142
89-332
938 (O)
94-225B
960717-1/2F
960926-1/4C
96-7-155
96-7-156
97-1-20
99-609 DP-A4
CP Clam 2 (O)

MLT 131 (O)
MLT 136
MLT 141 (O)
OLOL 2
SFGM
1003 (O)
1008 (O)
94-226B
CDC 9346-95
BUF 7211

Biotype

42° C

ODC

Indole

LPS Type

1

+

+

+

O2

1

+

+

+

O2

1
1
1
1
1
1
1
1
1
1

+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+

O3
O3
O3
O3
O3
O3
O3
O3
O3
O3

1

+

+

+

O3

1

+

+

+

O3

1

+

+

+

O3

1

+

+

+

O3

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

O3
O3
O3
O3
O4
O4
O4
O4
O4
O4
O4
O4
O4
O4
O4
O4
O4
O4
O4
O4
O6
O7
O7

1

+

+

+

O7
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Table 2.1 (cont.).
Strain
97-1-119
1015 (O)
541(Ø)-2A
541(Ø)-2AC
541(Ø)-32C
541(Ø)-9C
89-441
95-10-15
99-520 DP-B8
CDC 9005-97
DAL 7-9087
CDC 9049-96
ATL 61438(12)
CDC 9053-96
FLA 8869
CDC 9349-95
NSV 5736
1001 (O)
99-736 DP-C7
535
536
15-8-161
95-8-161
95-8-162
95-8-188
A8
Az
CECT 4606
CECT 4869
CECT 5198
CECT 5343
1000 (O)
1004 (O)
94-8-112
94-9-123
CDC 9026-95
LOS 6808
CECT 4604
CECT 4863
(ATCC 33817)
CECT 4867
CECT 5762
CG100
CP Sed 5 (O)
FB Oyster 11 (O)

1010 (O)
Biotype 3/1033
Biotype 3/12
NT = Nontypeable

Biotype
2
2
2
2
2
2
2
2
2

42° C
+
+
+
+
+
+
+
+
+

ODC
+
+
+
-

Indole
+
+
+
+
+
+

LPS Type
NT
NT
NT
NT
NT
NT
NT
NT
NT

2

+

-

+

NT

2

+

-

+

O1/O5

2

+

-

+

O1/O5

2

+

-

+

O1/O5

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-

O2
O2
O3
O3
O3
O3
O3
O3
O3
O3
O3
O3
O3
O3
O4
O4
O4
O4

2

+

-

+

O4

2

+

-

-

O4

2

-

+

-

O4

2
2
2
2
2
2
3
3

+
+
+
+
+
+
+
+

+
+
+
+

+
+
+
+
+
+

O4
O4
O4
O4
O4
O7
O3
O3
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FIG. 2.5. Vibrio vulnificus LPS serovar distribution in clinical and environmental samples.
Analysis included 123 isolates, 51 clinical and 72 environmental. Note the larger percentage of
serovar O1/O5 in clinical isolates as compared to the environmental ones. Lipopolysaccharide
serovars O3 and O4 dominated the environmental isolates and there was a higher percentage of
nontypeable isolates as well. The difference in the distribution of the LPS serovars between
clinical and environmental isolates was not significant (P=.7979).
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percentage (39%) of environmental isolates could not be typed. There was not a statistical
difference in the LPS serovar distribution between the clinical and environmental isolates
(P=.7979). However, if only isolates from the United States are analyzed there is a significant
difference between the clinical and environmental United States isolates (P=<0.001) with 37.3%
of the clinical isolates belonging to serovar O1/O5 (37.3%) and only 3.4% of the environmental
isolates belonging to serovar O1/O5. Again, most of the environmental isolates remained
nontypeable (38.9%).
The LPS serovar distribution of biotypes 1 and 2 is shown in Figure 2.6. The LPS
serovars in biotype 1 appeared to be evenly distributed between the LPS serovars with the
exception of serovars O6 and O7. Biotype 2, on the other hand, had a significantly larger
percentage of serovars O3 and O4 relative to the other LPS serovars and compared to the
percentage of serovars O3 and O4 in biotype 1. There was a statistically significant difference in
the LPS serovar distribution between biotype 1 and biotype 2 isolates (P=.0467).
The LPS serovar distribution between the United States and European isolates is shown
in Figure 2.7. All of the LPS serovars are evenly distributed among the USA isolates with the
exception of serovars O6 and O7, whereas only LPS serovars O3 and O4 were seen in European
isolates. Interestingly, all of the European isolates were able to be typed, whereas 35% of the
United States isolates could not be typed. The difference in the LPS serovar distribution between
the United States and European isolates was statistically significant (P=0.0060).
Discussion
Shimada and Sakazaki (87) initially proposed seven LPS serovars based on reactivity
with rabbit polyclonal antibodies. In 1991, Martin and Siebeling (86) reported five MAbs
recognizing five of the seven serovars proposed by Shimada and Sakazaki (87), and identified a
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FIG. 2.6. Vibrio vulnificus LPS serovar distribution in biotype 1 and biotype 2 isolates. Analysis
included 152 isolates, 113 biotype 1 and 39 biotype 2. Note the fairly even distribution of the
LPS serovars in biotype 1 with the exception of serovars O6 and O7. Lipopolysaccharide
serovars O3 and O4 dominated the environmental isolates and there was a lower percentage of
nontypeable isolates as well. The difference in the distribution of the LPS serovars between
biotype 1 and biotype 2 isolates was statistically significant (P=.0467).
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FIG. 2.7. Vibrio vulnificus LPS serovar distribution in isolates collected in the United States or
Europe. Analysis included 129 isolates, 114 from the USA and 15 from Europe. The LPS
serovars were evenly distributed in United States isolates with the exception of serovars O6 and
O7. Only LPS serovars O3 and O4 were found in the European isolates. As of this time, there
were no European isolates that were nontypeable. The difference in the distribution of the LPS
serovars between USA and European isolates was statistically significant (P=.0060).
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sixth serovar using affinity-purified anti-LPS immunoglobulin. Based on the work of Shimada
and Sakazaki, only one LPS serovar remained unidentified. Using the reagents of Martin and
Siebeling, Zuppardo et al. (88) showed that approximately 30% of V. vulnificus isolates could
not be typed indicating the need to expand the O-typing scheme developed by Martin and
Siebeling (86) to accommodate additional LPS serovars. In this study, Martin and Siebeling (86),
identified the isolates V. vulnificus 1008 (O) and 1003 (O) as not reacting with any of their MAbs
and suggested they may represent the other two serotypes proposed by Shimada and Sakazaki
(87). These were the strains that were used to produce MAbs to LPS in the hopes of completing
the O-typing system.
Monoclonal antibodies RS1 and RS2 were developed against hot water/phenol purified
LPS of V. vulnificus strains 1003 (O) and 1008 (O) respectively. The quality of the LPS was
assayed by the silver staining polyacrylamide gel method of Hitchcock and Brown (114). Upon
silver staining the LPS on the polyacrylamide gel, there was no evidence of a LPS ladder
commonly seen with other Gram-negative bacteria and indicating the presence of O-side chains
(Fig. 2.1). In V. vulnificus, however, a ladder-like LPS structure has never been observed when
silver staining a polyacrylamide gel (115, 120, 121). Analysis of the hot water/phenol extracted
LPS showed fast-migrating, low molecular weight band(s), which could represent the lipid A
plus core oligosaccharide portion of the LPS molecule.
RS1 and RS2 were shown to bind selectively to hot water/phenol purified LPS and whole
cells of V. vulnificus isolates 1003 (O) and 1008 (O) respectively (Fig. 2.2). They were also
tested against whole-cell and hot water/phenol extracts of V. vulnificus isolates 1001 (O), 1004
(O), 1005 (O), 1007 (O), and 1009 (O), representing O2, O4, O3, O1, and O5 serovars,
respectively. No cross-reactivity with any of the isolates used to generate Martin and Siebeling’s
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MAbs (86) was observed (Fig. 2.2). In addition to being screened against V. vulnificus isolates,
RS1 and RS2 were also screened against a panel of bacteria containing Gram-positive, Gramnegative, and other Vibrio spp. (Fig. 2.2). RS1 and RS2 reacted specifically with their
immunizing strains. Based on this pattern, the antigen specificities of RS1 and RS2 were
designated O6 and O7, respectively.
Western blot analysis on whole-cell lysates, proteinase K digested whole-cell lysates, and
hot water/phenol purified LPS were performed to ascertain the binding characteristics of RS1
and RS2. Polyclonal antibody bound only to the V. vulnificus whole-cell lysates and not to the
proteinase K digested lysates, indicating that the majority of the antibodies in these pools were
binding protein and not polysaccharides (Fig. 2.3). Neither RS1 nor RS2 reacted in the western
blot analyses with either of the lysates or the purified LPS preparations, suggesting that RS1 and
RS2 were probably recognizing conformational epitopes on LPS that were denatured during
either the separation or the transferring of the LPS molecule to the nitrocellulose membrane.
Using western blot analysis and polyclonal antibody, Amaro et al. (115) demonstrated
that V. vulnificus does possess high molecular weight O-side chains. They were only able to
demonstrate this for biotype 2 and suggested this was due to the homogeneity of biotype 2 LPS.
If Amaro et al. are correct, V. vulnificus 1003 (O) and 1008 (O) may not have reacted with
polyclonal antisera on western blots because they are both biotype 1 strains and therefore may
have more heterogeneity in their LPS. The lack of reactivity between the extracted LPS of V.
vulnificus 1003 (O) and 1008 (O) and polyclonal antisera also explains why there was no
reactivity with MAbs RS1 and RS2 on the western blot analysis.
In order to ascertain whether or not MAbs RS1 or RS2 bound to the LPS biomolecule,
TEM was employed. Figure 2.4 B and D clearly demonstrated the specificity of RS1 and RS2 for
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V. vulnificus 1003 (O) and 1008 (O) isolates respectively. RS1 selectively bound to the outer
membrane of V. vulnificus 1003 (O) and not to the extracellular polysaccharide. RS2, which
selectively bound to V. vulnificus 1008 (O), displayed a different binding pattern than RS1. It
appeared as though RS2 was potentially binding to the capsular material surrounding the
bacterium. The initial screening of hybridoma RS2 was performed on LPS purified by proteinase
K digestion of whole-cell lysates. The LPS purification procedure used by both Amaro et al.
(115) and Bahrani and Oliver (120) allows for the possibility that capsular polysaccharide
remained in the final purified product, leaving the possibility that RS2 was an anti-capsular
MAb. Vibrio vulnificus 1008 (O) LPS was then purified with the hot water/phenol method which
had been shown to produce a cleaner LPS preparation as compared to the proteinase K digestion
of whole-cell lysates (120). Subsequent rounds of screening RS2 were performed on the hot
water/phenol purified LPS and the antibody was shown to be reactive with this LPS prep as well
(Fig. 2.1), indicating RS2 was indeed an anti-LPS MAb.
It has been demonstrated that as many as 3 biotypes exist in V. vulnificus (19, 38).
Biochemical profiles have been used for the distinction between biotypes 1, 2, and 3. Biotype 1
organisms are classified as producing indole, growing at 42ºC, producing ODC, and being
pathogenic for mice; biotype 2 organisms are negative for the above biochemical tests and are
pathogenic for eels and mice (38). Interestingly of the 40 strains identified as biotype 2
organisms in this study most were negative for only one of the biochemical discrimination tests
and not all three. Thirteen eel pathogens were examined in this study; two isolates were negative
for ODC and growth at 42ºC, and seven isolates were negative for ODC only (Table 2.1).
Without the eel pathogenicity data, four out of thirteen of the eel pathogens were positive for all
of the discriminatory biochemical assays used in this study (Table 2.1) and would have been
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classified as biotype 1. These data suggest that utilizing biochemical profiles as the sole indicator
for biotype determination is not sufficient, and that host susceptibility should be included in the
final determination as well.
In this study, I typed the LPS of 154 strains of V. vulnificus isolated from clinical and
environmental sources from the United States, Europe, and Israel. It is important to note that the
MAb SM1, which was originally published by Martin and Siebeling as serovar 3 (86) was
referred to as serovar O1 by Zuppardo et al. (88). Likewise, serovar 1 originally published by
Martin and Siebeling was referred to as serovar O3. All serotyping data contained in this paper is
based on the classification system used by Zuppardo et al. (88). In the original LPS MAb paper,
Martin and Siebeling (86) claimed to have five MAbs capable of recognizing five distinct Oserovars. Subsequent work (88) showed that their reagents identified four distinct O-serovars,
and that a unique serovar, O1/O5, appeared in isolates that were simultaneously expressing both
the O1 and O5 O-side chains. Serovars O1 and O5 were co-expressed, however, reactivities
could be separated under certain culture conditions (Chapter 4). In my hands, I only observed the
O1/O5 serovar as well. This was in direct conflict with the data presented by Martin and
Siebeling (86). Martin and Siebeling recorded V. vulnificus isolates 1002, 1007, and 1013 as
being O1 and 1009 as being O5. In this study and in the study by Zuppardo et al. (30), these
isolates all typed as O1/O5. Discrepancies regarding serovars O2 and O4 were observed as well.
Martin and Siebeling (86) reported isolates 1000 and 1015 as nontypeable, however, in this study
they were typed as O4 and O2, respectively. A possible explanation is that the LPS serotype of
these strains changes with continued passage. There is no way to be sure that the isolates that
Martin and Siebeling were serotyping in 1991 are exactly the same as the isolates I have typed. It
is possible that the isolates in question may have acquired changes in DNA over time that may
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have led to changes in LPS epitope structure, thus the Martin and Siebeling isolates could be
serologically distinct from the isolates typed in this study. There are a multitude of genes,
including epimerases, glycosyl transferases, galU and galE, flipases, sugar dehydrogenases,
isomerases, and regulators of O-antigen length that are responsible for LPS structure (122-126),
thus there is no definitive way to say which genes, if any, have changed with continuous passage.
To determine whether or not MAbs are effective reagents in epidemiological analysis of
V. vulnificus, isolates were grouped based on whether the isolate came from a clinical source, its
biochemical characteristics, and whether the isolate originated from the United States or Europe.
Analysis of clinical versus environmental isolates revealed that serovar O1/O5 was dominant in
clinical isolates and that serovars O2, O3, and O4 were dominant in environmental isolates (Fig.
2.5). Siebeling (111) proposed that the O1/O5 serovar is unique to the Gulf of Mexico. If so, the
data may be skewed as the majority of clinical isolates used in the study came from patients who
reside in states bordering the Gulf of Mexico. In this study, there were no clinical isolates from
outside of the Gulf Coast region except for the two biotype 3 isolates from Israel, and one
clinical isolate from Denmark. Each of the Israel isolates belonged to serovar O3 and the Danish
isolate belonged to serovar O4. However, if only clinical and environmental isolates from the
United States are used in the comparison, a significant difference is found with O1/O5
dominating the clinical specimens. There was also a larger percentage of nontypeable isolates in
the environmental group as compared to the clinical group. The reagents used in this study were
developed using clinical isolates as the immunizing strains (86); this could explain why such a
high percentage of clinical isolates are typed compared to environmental isolates. Alternatively,
there may be many more LPS serovars in the environment than the proposed seven, and only a
limited number are capable of causing disease. It is possible that switching of the LPS in vivo is a
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mechanism for evading host resistance in a clinical setting, however this has never been
demonstrated experimentally. Alternatively, some LPS serovars may be more virulent than
others, but there have been no studies to support this hypothesis.
Lipopolysaccharide serovar distributions in biotype 1 isolates were evenly distributed
except for serovars O6 and O7, which were not common (Fig. 2.6). In contrast, the distribution
pattern in biotype 2 isolates was heavily slanted towards O3 and O4. The differences in LPS
distribution in biotype 1 versus biotype 2 were statistically significant (P=.0467). The large
majority of the biotype 2 isolates used in this study were from diseased eels from Spain and
Denmark and all of the diseased eel isolates were typed as O3 or O4. This may have skewed the
biotype 1 and biotype 2 distributions.
The LPS distribution in the United States and European isolates (Fig. 2.7) was highly
significant. The LPS serovars were evenly distributed in United States isolates except for O6 and
O7; however, all the European isolates were either O3 or O4. These results confirm the findings
of Hoi et al. (12) that biotype 2 eel pathogens usually belong to LPS serovars O3 and O4.
Interestingly the polyclonal antibody pool to serogroup E, as defined by Amaro et al. (85) seems
to bind to the same or similar LPS epitope as MAb identified serovar O4 (6/6 isolates), however
serogroup A defined by Amaro (84) did not show the same correlation with the O3 (3/11
isolates) MAb. The difference in the LPS distribution between the United States and European
isolates is statistically significant (P=.0060), but the sample size for European isolates is small as
compared to the number of United States isolates.
While the panel of strains used in this study was large enough for statistical analysis, they
were not evenly distributed amongst the subgroups. A more balanced and representative panel of
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isolates would provide a more accurate analysis of LPS distribution patterns on both a regional
and global scale.
Testing and identification of clinically relevant serovars in seafood followed by the
removal of infected raw seafood could significantly decrease incidence of human disease.
Currently, there are seven LPS serovars that can be recognized by MAbs, and as of this time,
there is no research that indicates that one LPS serovar is more virulent than the others. The use
of MAbs reduces the cross-reactivity usually associated with polyclonal antibodies and provides
a reproducible, workable platform for typing V. vulnificus isolates. While there are more
discriminatory methods for grouping V. vulnificus such as PFGE (92) and ribotyping (12), these
methods are costly and time consuming, and neither correlates directly with a cell surface
virulence marker. Of the three major cell surface antigens, neither the flagella nor the capsule
provide a good basis as a serotyping system as the flagella has a species specific epitope (80) and
the capsule is poorly immunogenic (82), leaving LPS as the remaining cell surface antigen to
target. While the addition of two new MAbs against the LPS of V. vulnificus has increased the
overall effectiveness of the LPS serotyping system, it is clear that these new MAbs only
recognize a small percentage of isolates, resulting in a large pool of isolates still left to be typed.
These data suggests that in order to complete the LPS serotyping system, more MAbs will need
to be produced to account for more of the LPS variability present in V. vulnificus.
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CHAPTER 3:
PHAGE-DISPLAY OF ANTIBODIES AS A SUBSTITUTE FOR
MONOCLONAL ANTIBODIES
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Introduction
With the ever increasing cost of fetal calf serum and other culture supplements, and the
declining use of ascites production in living mice, there is a growing need for diagnostic
antibodies that do not rely upon expensive cell culturing or the use of animals. Current methods
for generating antibodies are limited to the production of polyclonal and MAbs. Polyclonal
antibodies are time consuming, require large amounts of animals, and produce antibodies capable
of binding to a wide array of antigens. Hybridoma technology has improved greatly over the last
30 years and while having the advantage of recognizing a single epitope, is still costly and time
consuming. While the idea of utilizing pre-existing MAbs as a source of RNA for the generation
of PDAbs does not diminish the amount of time it takes to initially generate the MAb, it does
have the advantage of decreased cost of producing and maintaining the antibodies.
Over the past 17 years, MAbs have been the reagent of choice for serotyping the
bacterium Vibrio vulnificus as they do not display the cross-reactivity of polyclonal antibodies.
Monoclonal antibodies have been developed against the LPS (86), the flagella (80), the capsule
(83), and a heat-stable internal protein (60) of V. vulnificus. The in vivo and in vitro production
of antibodies has become both expensive and time consuming, resulting in the need for a
technique that is capable of producing specific antibodies that are easy and inexpensive to both
produce and maintain.
In 1985, G.P. Smith, developed the technique of “phage-display” by fusing a portion of
the Eco RI protein to the gene III coat protein of a filamentous bacteriophage (127). Years later,
W.D. Huse and Richard Lerner were able to create a combinatorial library of immunoglobulin
genes cloned in phage lambda (128). It was the fusion of Lerner’s library with Smith’s “Phagedisplay” technique that led to the formation of PDAbs.
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The technique of phage-display provides a system for the cost-effective maintenance of
pre-existing MAbs. Cloning of immunoglobulin variable regions, either antigen binding
fragments (Fab) or single chain variable fragments (scFv), into the gene III region in a phagemid
(bacteriophage/plasmid hybrid) allowed for the production of PDAbs utilizing E. coli without the
need for expensive cell culture medium or the production of ascites fluid (129). The source of
the antibody DNA can be native or from previously existing MAbs. Resulting PDAbs were
shown to be biochemically similar to the parent MAb (130-133).
The MAb, RS1, which binds to the LPS of V. vulnificus serovar O6, was chosen for
expression in a phage-display system. The phagemid pComb3X was selected as the cloning
vector as it had been previously shown to be a sufficient vector for the cloning of murine
immunoglobulin genes (134-136). In this report, I describe the generation of clone, PJ1,
expressed in E. coli XLI-Blue and tested for anti-V. vulnificus serovar O6 LPS specificity in both
whole-cell and LPS ELISAs and transmission electron microscopy. The report also includes
description of some of the technical problems associated with the system including the need to
develop new scFv primers to be used in the pComb3X phagemid vector. This study
demonstrated that the resulting PDAbs are a viable alternative for traditional MAbs when used as
a serological reagent for V. vulnificus.
Materials and Methods
Ribonucleic Acid Extraction. The hybridoma RS1 cells were maintained as previously
described (Chapter 2). Whole-cell RNA was isolated by addition of TRI REAGENT® (Molecular
Research Center, Inc., Cincinnati, OH) at a concentration of 1 ml/107 cells of RS1. Homogenized
cells were incubated for 5 min at room temperature and 0.1 ml of 1-Bromo-3 Chloropropane
(Molecular Research Center, Inc.) was added per 1 ml of TRI REAGENT®. The sample was
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shaken vigorously for 15 sec and incubated for 15 min at room temperature. The sample was
then centrifuged at 12,000 x g for 15 min at 4°C. The RNA (aqueous phase) was transferred to a
fresh tube and 0.5 ml of isopropanol/1 ml of TRI REAGENT® used in the initial homogenization
was added. The mixture was incubated for 10 min at room temperature. The sample was
centrifuged at 12,000 x g for 8 min at 4°C. The supernatant was discarded and the pellet was
washed with 75% ethanol (EtOH). Lastly, the RNA was spun at 7,500 x g for 5 min at 4°C, and
the RNA pellet was allowed to air dry for 5 min. The RNA pellet was dissolved in 250 µl of
RNase-free H2O and stored at -20°C.
Generation of cDNA. Hybridoma cDNA was generated from whole-cell RNA using the
Invitrogen SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen Corporation,
Carlsbad, CA) as described by the manufacturer.
Amplification of Light Variable and Heavy Variable cDNA. RS1’s light chain DNA was
generated by PCR using the following reagents in a 100 µl reaction: 20 µl of 5X Phusion HF
Buffer (New England Biolabs, Ipswich, MA) or 10 µl of 10X Thermopol Reaction Buffer (New
England Biolabs) or 10 µl of 10X Thermophilic DNA Polymerase Buffer (Promega, Madison,
WI), 2 µl of 10 mM dNTP mix (Applied Biosciences, Fresno, CA), 1 µl of 60 µM kappa
forward primer mix [(MWG Biotech, High Point, NC) (137)], 1 µl of 60 µM kappa reverse
primer mix [(MWG Biotech) (137)], 2 U of Phusion™ high-fidelity DNA polymerase (New
England Biolabs) or 2 U of VentR® DNA Polymerase (New England Biolabs) or 4 U of Taq
DNA Polymerase (Promega), 1 µg of cDNA, and nuclease-free dH2O to bring the reaction
volume up to 100 µl.
RS1’s heavy chain DNA was generated through standard PCR using the above reagents
in the light chain 100 µl reaction except that 1 µl of a 60 µM heavy forward primer mix [(MWG
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Biotech) (137)] and 1µl of a 60 µM heavy reverse primer mix [(MWG Biotech) (137)] or 1 µl of
a 60 µM modified heavy reverse primer mix [(Sigma Genosys, The Woodlands, TX) (Table 3.2)]
were used.
Both the light and heavy PCR reactions were carried out in an Applied Biosystems
GeneAmp PCR System 2400 thermal cycler (Fresno, CA) utilizing the following conditions:
98°C for 30 sec, 30 cycles of 98°C for 10 sec, 56°C for 30 sec, 72°C for 30 sec, followed by
72°C for 10 min. The reactions were then held at 4°C until the samples were removed from the
thermal cycler. The DNA was stored at -20°C.
Generation of Overlap from Light and Heavy DNA PCR Amplicons. Hybridoma RS1’s scFv
was generated through an overlap PCR combining the kappa and heavy chain DNA. The
following reagents were used in a 100 µl reaction: 20 µl of 5X Phusion HF Buffer (New
England Biolabs) or 10 µl of 10X Thermophilic DNA Polymerase Buffer (Promega), 2 µl of 10
mM dNTP mix (Applied Biosciences, Fresno, CA), 1 µl of 60 µM RSC-F sense primer [(MWG
Biotech) (Table 3.1)], and 1 µl of 60 µM RSC-B reverse primer [(MWG Biotech) (Table 3.1)] or
1 µl of 60 µM Mod-RSC-B reverse [(Sigma Genosys) (Table 3.3)], 2 U of Phusion™ high-fidelity
DNA polymerase (New England Biolabs) or 4 U of Taq DNA Polymerase (Promega), 1 µg of
cDNA, and nuclease-free dH2O to bring the reaction volume up to 100 µl.
The overlap PCR reactions were carried out in an Applied Biosystems GeneAmp PCR
System 2400 thermal cycler utilizing the following conditions: 98°C for 30 sec, 25 cycles of
98°C for 10 sec, 56°C for 30 sec, and 72°C for 30 sec, followed by 72°C for 7 min. The reactions
were then held at 4°C until the samples were removed from the thermal cycler. The DNA was
stored at -20°C.
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Analysis of PCR Amplicons. Light and heavy chain PCR amplicons were analyzed on a 2%
TAE (0.04 M Tris Base, 0.04 M acetate, 0.001 M EDTA) agarose gel containing ethidium
bromide (EtBr) after being electrophoresed at 80 V for 1 h and 5 min. Single chain variable
fragments were analyzed on a 1% TAE agarose gel containing EtBr after being electrophoresed
at 80 V for 1 h and 5 min. Other times, PCR amplicons were visualized using the Cambrex
FlashGel™ system (East Rutherford, NJ). The FlashGel™ was never used for gel extraction, only
for quick visual confirmation of PCR amplicons. Amplicons were visualized and gel images
were made on a Bio Rad Gel-Doc XR Molecular Imager® GelDoc™ XR System (Hercules, CA)
imaging system. The sizes of the bands of interest were (~350 base pairs (bp) for the kappa
chain, ~400 bp for the heavy chain, and ~800 bp for the scFv overlap.
Gel Purification of DNA. DNA was purified from gels using the Zymoclean™ Gel DNA
Recovery Kit (Zymo Research Corporation, Orange, CA) with the following modification: DNA
was eluted from the column by the addition of 2 mM Tris-Cl pre-heated to 70°C and incubating
the column for 1 minute at room temperature. Gel-purified DNA was stored at -20°C.
Sfi I Restriction Digestion. Sfi I digests of scFv overlaps contained 5 µg of overlap DNA, 20 U
of Sfi I per µg of DNA, appropriate amount of Sfi I restriction buffer, and dH2O to bring the
reaction volume up to 100 µl. Digests were incubated for 5 h at 50°C. Digests were EtOH
precipitated and washed (138), gel-purified as described above, and stored at -20°C.
The Sfi I digest of pComb3X contained 20 µg of vector DNA, 120 U of Sfi I, appropriate
amount of Sfi I restriction buffer, and dH2O to bring the reaction volume up to 200 µl. Digests
were incubated, gel-purified, and stored as described above.
pComb3X Phagemid Vector. The phagemid vector pComb3X, which contains a carbenicillin
resistance selective marker, was a gift from Carlos Barbas, III (Scripps Institute, LaJolla, CA). It
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was chemically transformed (139) into E. coli GM 2163 (Dam-). The phagemid was maintained
in E. coli, and purified using QIAGEN’s QIAfilter Plasmid Maxi prep kit (Valencia, CA),
digested with Sfi I as described above, and purified with the QIAquick® Gel Extraction Kit
(Qiagen, Valencia, CA).
pComb3X and scFv Ligation. The phagemid containing the scFv was prepared by adding 100
ng of digested scFv overlap and 200 ng of digested pComb3X vector to a reaction mixture
containing 400 U of T4 DNA Ligase (New England Biolabs), T4 Ligase Buffer, and enough
dH2O to bring the reaction volume up to 20 µl. The reaction mixture was incubated overnight at
16ºC, and the T4 DNA Ligase was inactivated by heating at 65ºC for 10 min.
Transformation. Electrocompetent XL1-Blue MRF΄ Blue cells were either purchased
(Stratagene, Cedar Creek, TX) ready for use or prepared by the following method. XL1-Blue
MRF΄ Blue cells were grown in L-Broth at 37ºC until an OD600nm of 0.5-1.0. Cells were
centrifuged at 4000 x g for 7 min at 4ºC and the pellet resuspended in 1 volume of sterile, cold
dH2O and centrifuged as before. Cells were resuspended in 0.5 volumes of sterile, cold dH2O and
centrifuged as before and repeated. Cells were resuspended in 0.02 volumes of sterile, cold dH2O
and centrifuged as before. Lastly cells were resuspended in 0.002 to 0.003 volumes of sterile,
cold, filter-sterilized, 10% glycerol (filter-sterilized), and stored at -70ºC.
Electroporation was performed as described by Rader, Steinberger, and Barbas III (140)
with the following modifications. The ligated sample and electroporation cuvette (Bio Rad) were
placed on ice for 10 minutes meanwhile thawing 40 µl of electrocompetent E. coli cells. A 1 ml
pipette tip (with a snipped off end) was used to add the E. coli to the ligated sample. The sample
was mixed, transferred to the electroporation cuvette, and incubated for 1 min on ice. The sample
was electroporated at 1.3 kV, 25 µF, and 200 Ω, and flushed with 1 ml of L-Broth at room
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temperature. The sample was shaken at 250 rpm for 1 h at 37ºC. Individual colonies from the
phage titer plates were propagated in Super Broth (SB) (10% MOPS, 30% tryptone, and 20%
yeast extract) containing carbenicillin (40 µg/ml) and tetracycline (50µg/ml) overnight.
Preparation of Monoclonal Phage-Displayed scFv Stocks. Monoclonal phage stocks were
prepared as described by Siegel (141) with the following modifications. Overnight cultures (0.3
ml) was added to 30 ml of SB containing carbenicillin (40 µg/ml) and tetracycline (50 µg/ml)
and incubated at 37ºC with shaking at 300 rpm until the cultures reached an OD600nm of 0.3.
VCSM13 helper phage (2.5 x 1011 pfu) was added to each culture and the cultures were
incubated for 15 min at 37ºC. The cultures were incubated with shaking for an additional 2 h at
37ºC. Lastly, kanamycin was added at a final concentration of 70 µg/ml and the temperature was
lowered to 30ºC and the cultures were incubated for overnight at 37ºC with shaking. Overnight
cultures were centrifuged at 5300 x g for 10 min at 4ºC. The phage containing supernatant was
collected and centrifuged at 28,000 x g for 10 min at 4ºC. Phage containing supernatants were
either stored over chloroform at 4ºC, PEG precipitated (141), or sodium azide was added to a
final concentration of 0.005% and stored at -20ºC.
Screening of Monoclonal Phage. Monoclonal phage-displayed scFv isolates were screened on
V. vulnificus 1003 (O) and 1008 (O) by whole-cell ELISA as previously described (Chapter 2).
Phage binding to only V. vulnificus 1003 (O) were screened against V. vulnificus 1003 (O)
purified LPS as described in chapter 2. Phage, binding to both the whole-cell and LPS antigens,
were then used to reinfect E. coli, and glycerol stocks containing the phagemid of interest were
stored at -70ºC.
Immuno-Electron Microscopy. Immuno-electron microscopy was performed as described in
chapter 2 with the following modifications. Vibrio vulnificus 1003 (O) cells and freshly-prepared
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PJ1 or phage derived from pComb3X that did not have a scFv insert were mixed and incubated
for 15 min at 30ºC. The phage and cells were then incubated on the copper TEM grid for 2 min
at room temperature. The grid was washed once in dH2O, and negatively stained with 2% uranyl
acetate for 5 sec.
Results
Amplification of Light and Heavy Chain cDNA Using Published Primers. Monoclonal
antibody, RS1, secretes an IgG1 heavy chain and a kappa light chain (Table A.2). The goal of
this work was to generate a functional scFv molecule. The heavy and light chain genes are coded
on two separate mRNA molecules; therefore, two separate PCR reactions were needed to
amplify the corresponding cDNA for both the heavy and light chain DNA. Figure 3.1A shows
the amplification of heavy and light chain DNA when using the light and heavy chain primers
originally published by Andris-Widhopf et al. (137). The amplified heavy chain and kappa chain
were then used in an overlap reaction (Fig. 3.1B) using the originally published overlap primers
(137). Unfortunately, the published overlap primers did not yield the desired scFv fragment of
800 bp, rather, DNA bands approximately 100 bp in length were observed suggesting the
possibility of the formation of primer dimers.
Examination of Overlap Primers for Primer Dimer Formation. Each overlap primer was
examined for flaws that could possibly lead to the development of the 100 bp fragment. On both
the sense and reverse overlap primers a palindrome was located on the 3’ end (Table 3.1). Each
overlap primer was further examined in PCR conditions to see if they were contributing to the
formation of the 100 bp fragment. Multiple combinations of primers with and without template
were assayed for primer dimer formation (Fig. 3.2). Although the combination of RSC-F and
kappa template DNA produced a primer dimer (Fig. 3.2, Lane 3), there was no evidence of
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FIG. 3.1. Heavy, light and scFv overlap with previously published primers. (A) Light and heavy
chain DNA gel showing 350 bp kappa chain DNA amplicons in lane 1 and the 425 bp heavy
chain DNA amplicons in lane 2. (B) Overlap PCR DNA gel showing the formation of primer
dimers (~125 bp) and lack of the scFv overlap PCR amplicon around the 800 bp region in
replicate lanes.
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Table 3.1. Overlap extension primers for phage-display.
RSC-F (sense)

5'GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC3'

RSC-B (reverse)

5'GAGGAGGAGGAGGAGGAGCCTGGCCGGCCTGGCCACTAGTG3'

Palindromic sequences are in bold.

Table 3.2. Modified heavy primers for overlap extension.
Mod-MSCG1ab-B

5’GGATTGCTACTCGTCTGTGGCCGGCCTGGCCACTAGTGACAGATGGGGSTGTYGTTTTGGC3’

Mod-MSCG3-B

5’GGATTGCTACTCGTCTGTGGCCGGCCTGGCCACTAGTGACAGATGGGGCTGTTGTTGT3’
5’GGATTGCTACTCGTCTGTGGCCGGCCTGGCCACTAGTGACATTTGGGAAGGACTGACTCTC3’

Mod-MSCM-B

18 bp DNA sequences upstream of Sfi I site from which to amplify overlap in bold.

Table 3.3. Modified overlap reverse primer for overlap extension.
Mod-RSC-B

5’GGATTGCTACTCGTCTGTG3’
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FIG. 3.2. Analysis of original sense and reverse overlap primers for primer dimerization. The
attempted amplification of heavy chain DNA using heavy chain DNA template, the heavy sense
primer, and overlap reverse primer, RSC-B, is shown in lane1. The PCR assay in lane 2
contained no template DNA and only primer RSC-B. Note the presence of the 100 bp primer
dimer in both lanes 1 and 2. Lane 3 contains a successful amplification of kappa chain DNA (350
bp) using kappa chain DNA template, overlap sense primer RSC-F, and kappa reverse primers.
The PCR assay in lane 4 contained no template DNA and only primer RSC-F. Note the lack of
the 100 bp primer dimer in lane 4. The PCR assay in lane 6 contained no template DNA, and
only the primers RSC-F and RSC-B. Note the 100 bp primer dimer.

58

primer dimer formation when only RSC-F was included in the assay. The only primer that
produced dimers when used in PCR with and without template was primer RSC-B.
Modification of Heavy and Overlap Reverse Primers. In order to circumvent the formation of
primer dimers in the overlap reaction due to overlap primer RSC-B, new primers were designed
to amplify heavy chain DNA (Table 3.2) as well as a new reverse overlap primer (Table 3.3) to
aid in scFv generation. The addition of 18 nucleotides on the 5’ end of the heavy primers allowed
for a sequence of nucleotides to which a new overlap reverse primer could bind and still allowed
for the cloning of an Sfi I restriction site into the heavy chain DNA (Fig 3.3A). The heavy chain
DNA amplified with the new heavy reverse primers (Mod-MSCG1ab-B, Mod-MSCG3-B, and
Mod-MSCM-B) contained the additional 18 bp sequence which could be used as a suitable
template for the scFv overlap amplification. Utilizing the new overlap primer, Mod-RSC-B,
produced no primer dimers and allowed for the formation of the 800 bp scFv overlap (Fig. 3.3B).
Replication of MAb RS1’s cDNA for Phage-Displayed Antibody Production. Amplification
of heavy and light chain DNA was originally conducted using Taq polymerase. In my hands, I
was unable to use Taq polymerase to generate a scFv fragment raising the possibility that Taq
introduced a mutation that was subsequently inhibiting the successful formation of the scFv
overlap. In order to ensure that the cDNA of MAb RS1 was faithfully replicated, the high fidelity
enzymes VentR® and Phusion™ were selected for amplification of light and heavy chain DNA.
While the enzyme VentR® was able to amplify heavy chain DNA, it was unable to amplify kappa
chain DNA (Fig. 3.4A, Lane 2). Phusion™, another high-fidelity DNA polymerase, was then
used and assayed for the ability to amplify both heavy and light chain DNA. Figure 3.4B, shows
that Phusion™ was able to successfully generate both kappa (lane 1) and heavy chain (lane 2)
PCR amplicons. Kappa chain and heavy chain DNA amplified by Phusion™ DNA polymerase
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FIG. 3.3. Heavy chain and scFv overlap amplification with modified primers. (A) Amplification
of heavy chain DNA using modified primers. Note the absence of the 100 bp primer dimer. (B)
Amplification of scFv overlap using original overlap sense primer with modified overlap reverse
primer. PCR product of approximately 800 bp is the scFv.

60

FIG. 3.4. Light and heavy chain amplification with high-fidelity DNA polymerases. (A)
Amplification of heavy chain (lane 1) and kappa chain (lane 2) DNA with VentR® DNA
polymerase. Note the lack of a kappa chain PCR amplicon. (B) Amplification of kappa chain
(lane 1) and heavy chain (lane 2) DNA with Phusion™ DNA polymerase.
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were gel-purified and used as the template DNA for the scFv overlap reaction. Figure 3.5 shows
the generation of the scFv amplicon using kappa and heavy chain DNA as template DNA. There
was no indication of primer dimers. The residual band approximately 475 bp in length was
residual heavy chain DNA that was not consumed in the PCR.
Transformation of RS1 Overlap scFv. Once the scFv fragment was successfully cloned into
pComb3X, the phagemid was transformed into commercially-prepared competent E. coli XL1Blue MRF΄. The transformation yielded 1.5 X 103 total transformants. Since this was below the
expected value of approximately 5 X 107 transformants, the transformation was repeated using
E. coli XL1-Blue MRF΄ cells that were made electrically competent the day of the
transformation. This transformation yielded 1.05 X 104 total transformants. Although this was
still below the expected value, nine colonies, each containing a phagemid with an anti-V.
vulnificus 1003 (O) scFv insert, were picked and utilized for the generation of PDAbs.
Comparison of Binding Characteristics of RS1 and PJ1. Phage-displayed antibodies were
developed from the phagemid containing clone termed PJ1. The hybridoma RS1, which produces
a MAb specific for V. vulnificus 1003 (O) LPS, was the source of the RNA and therefore the
resulting PDAb should also have been specific for V. vulnificus 1003 (O) LPS. PJ1, was tested
by whole-cell and LPS ELISA against strains 1003 (O) and 1008 (O) of V. vulnificus. Table 3.4
shows the comparison of binding characteristics of PDAb, PJ1, and RS1, the MAb from which
PJ1’s scFv was derived, and their capacity to bind 1003 (O) LPS selectively. While both RS1
and PJ1 bound selectively to their immunizing strain 1003 (O), they did not bind strain 1008.
PJ1 Immuno-Electron Microscopy. The binding of PJ1 to the LPS of V. vulnificus 1003 (O)
was visually confirmed through electron microscopy. Figure 3.6 shows the comparable binding
of PJ1 and RS1 to the 1003 (O) LPS. Panel A shows the general size and shapes of M13 phage
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FIG. 3.5. Generation of scFv fragment (~825 bp) using heavy and kappa chain template DNA
generated through PCR using Phusion™ DNA polymerase. The band approximately 475 bp is
residual heavy chain template DNA left in the PCR reaction.
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Table 3.4. A comparison of monoclonal and phage-displayed
antibodies against Vibrio vulnificus 1003 (O).
Bacterial Cells
V. vulnificus 1003 (O)
V. vulnificus 1008 (O)

MAb: RS1
++++a
0

0 = 0.0-0.1 ODU, ++++ ≥ 0.7 ODU
a = whole-cell and LPS ELISA assays
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PDAb: PJ1
++++a
0

A

B

C

D

FIG. 3.6. Electron micrographs of phagemid and monoclonal antibody binding to Vibrio
vulnificus 1003 (O). (A) Size comparisons of flagella (on left) and phagemid (on right). (B)
Binding of MAb, RS1, and (C) phagemid, PJ1, to the LPS of V. vulnificus 1003 (O). Note the
clumping binding patterns in both RS1 and PJ1. (D) Generic phagemid derived from pComb3X
lacking an anti-V. vulnificus 1003 scFv insert incubated with V. vulnificus 1003 (O). Black bars
represent 0.1 µm in panels A and C and 1 µm in B and D.
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that have been negatively stained. Panel B and C show the similar binding locations of PJ1 and
RS1. The binding of RS1, which has been labeled with colloidal gold, is shown in panel B, and a
similar binding pattern in panel C is also observed with PJ1. In panel B, it appears as if RS1 is
actually binding to the outer membrane as opposed to the capsule. PJ1, which should contain the
scFv of RS1, binds in a similar manner, and indeed it does as seen in panel C. The electron
micrograph shows the phage penetrating capsular material and binding to the outer membrane of
the cell. Panel D is phage derived from pComb3X that does not contain a scFv and does not bind
to V. vulnificus 1003 (O).
Discussion
In this study, the phagemid vector, pComb3X, was chosen because it had previously been used in
the cloning of murine immunoglobulin cDNA (134-136) and because of the Sfi I restriction sites
in the scFv cloning region. The use of Sfi I cloning sites in pComb3X was unique in that the
restriction sequence (5’GGCCNNNNˇNGGCC3’) allowed unidirectional cloning even though
only one restriction enzyme was used making this an ideal choice as a phagemid. While I was
able to generate light and heavy chain DNA from the cDNA of RS1 (Fig. 1A) using previously
published primers for use with pComb3X (134, 137), I was unable to successfully generate the
target scFv overlap. Instead, a band of approximately 100 bp in length was observed (Fig. 1B)
indicating one or both of the overlap primers was contributing to the formation of primer dimers.
Analysis of both the original sense and reverse overlap primers revealed a palindromic sequence
on the 3’ end of each primer (Table 3.1). Careful analysis of the primers RSC-F and RSC-B
under PCR assay conditions revealed that although RSC-F contained a six base pair palindrome,
it was the eight base pair palindrome on the 3’ end of RSC-B that was contributing to the
formation of primer dimers (Fig. 3.2). The smaller product was favored in the PCR reaction and
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sufficient overlap product was not produced. Because RSC-B’s complementary binding site was
cloned into the heavy chain DNA in the first round of PCR, new heavy reverse primers and a
new overlap reverse primer were designed.
New heavy reverse primers, Mod-MSCG1ab-B, Mod-MSCG3-B, and Mod-MSCM-B
were designed to incorporate an 18 bp sequence upstream of the Sfi I site (Table 3.2) from which
the modified reverse overlap primer Mod-RSC-B (Table 3.3) could prime. Use of the modified
heavy reverse primers in conjunction with the original heavy forward primers allowed for the
amplification of heavy chain DNA while not producing any primer dimers (Fig. 3.3A). The
heavy chain DNA was larger than expected at ~500 bp. This could be explained as the modified
heavy reverse primers were longer than the original ones.

The use of Mod-RSC-B in

conjunction with RSC-F to produce a scFv DNA fragment of approximately 800 bp indicated
that the modified heavy primers were successful in incorporating the 18 bp sequence upstream of
the Sfi I site on the heavy chain DNA. In addition, Mod-RSC-B did not form primer dimers and
was capable of binding to the inserted 18 bp sequence on the heavy template DNA. Successful
generation and amplification of the scFv fragment indicated that the newly designed primers
were superior to the original published primers and could be used with the pComb3X display
system.
In order to produce a PDAb with a scFv that had a similar amino acid structure to the Fv
(variable fragment) region of RS1, high-fidelity DNA polymerases were necessary. The initial
selection of VentR® DNA polymerase proved to be a poor choice. While VentR® was able to
replicate heavy chain DNA, the enzyme failed in the ability to generate any kappa chain DNA
(Fig. 3.4A). The fact that VentR® was able to amplify heavy chain DNA and not kappa chain
DNA was not surprising as VentR® often has a difficult time with cDNA templates (142). A
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second high-fidelity enzyme, Phusion™, was tested. The Phusion™ enzyme was able to amplify
heavy and kappa DNA (Fig. 3.4B) and was also able to successfully generate and amplify the
scFv overlap fragment (Fig. 3.5). This confirmed the success of the modified heavy and overlap
primers.
Once the scFv was cloned into pComb3X, the electroporation of the vector produced
unexpected results. The advertised cloning efficiency of electrocompetent E. coli XL1-Blue
MRF΄ was 1 X 1010 transformants/µg of DNA (Stratagene). The transformation efficiency, while
lower than expected, can be explained by the potential of the scFv insert being toxic for the host
as has been previously reported (143).
Although the scFv insert may have been toxic, there were still transformed cells, and
because of the use of high-fidelity DNA polymerases, each of the transformants should be
capable of producing phage having similar binding characteristics as monoclonal RS1. It should
be noted that different host bacterial strains may produce different transformation efficiencies.
Although E. coli XL1-Blue MRF΄ produced low transformation efficiencies, Table 3.4 and
Figure 3.6 provide direct evidence that PJ1 specifically binds to V. vulnificus 1003 (O) and that it
is specific for the LPS serovar O6. In future studies, alternative host strains may be able to yield
higher transformation efficiencies but they will have to be tested empirically to determine
whether this is possible.
These data presented here provide proof that scFv phage-display can be utilized as a
serotyping reagent for V. vulnificus LPS as previously described for other species (135). These
data suggest that PDAbs are equivalent to traditional MAbs in terms of specificity although the
affinity of the resulting PJ1 was not tested. In terms of affinity and avidity, PJ1 should be the
same as RS1. The fact that PJ1 has the same scFv sequence as RS1 should result in similar
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folding of the antigen binding site resulting in a similar binding affinity as RS1. Also, because
PJ1 was generated with a scFv overlap with a short linker, two scFvs should bind in a 3D
structure (diabody) yielding two binding sites which would provide PJ1 with the same avidity as
RS1. This should result in an antibody with similar binding characteristics as RS1. Phagedisplayed antibodies are cheaper to both maintain and store. In addition, existing PDAbs can be
genetically modified with gene shuffling protocols (144-148) to yield antibodies of greater
sensitivity.
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CHAPTER 4:
TYPING COLONY VARIANTS OF VIBRIO VULNIFICUS
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Introduction
Vibrio vulnificus, a marine bacterium capable of causing human disease has been
implicated as the etiological agent responsible for over 95% of deaths related to seafood
consumption in the United States of America (149). Infection usually occurs from the ingestion
of raw oysters or through contact of an open wound with contaminated seawater. It has been
shown that the capsule is the primary virulence factor in terms of causing disease in patients (72,
73, 79). Many isolates of V. vulnificus produce different levels of capsular polysaccharide (71).
Isolates having a thick capsule give rise to colonies that have smooth, mucoid, opaque
phenotypes, whereas colonies that either have reduced capsule expression or no capsule at all
have smooth, dry, translucent phenotypes (73).
In culture many opaque strains have spontaneously given rise to translucent phenotypes
(83, 150). This observation has led many investigators to examine the relationship between
opaque and translucent colony variants. Comparisons of opaque and translucent colonies has
shown that the opaque variants are much more virulent as compared to their translucent variants
(72, 73, 150). Many studies have also shown that there are multiple levels of capsule expression
between opaque and translucent colonies suggesting that there are various levels of translucency
(79, 83). Recently, a stable intermediate phenotype containing less capsule than opaque variants
and more capsule than translucent variants has been described (77).
Switching of V. vulnificus isolates from the opaque to translucent phenotype has been
reported to occur at frequencies of approximately 10-5 to 10-4 (72, 78, 79). During the switch
from an opaque phenotype to a translucent phenotype, it was speculated that there may be an
LPS serotype switch occurring simultaneously with the loss of capsule expression, suggesting a
correlation between capsule and LPS types (111). While this phenomenon has been observed in
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Vibrio cholerae (76) there has been no study examining this phenomenon in V. vulnificus. In
order to test the hypothesis, three different culturing methods were used to generate translucent
morphotypes from opaque isolates. These were stagnant cultures on HI plates incubating at room
temperature, and serial dilutions of overnight cultures utilizing two different methods of aeration.
In the study reported here, a multitude of colony variants were observed based on method of
culture and no observed correlation between loss of capsule expression and LPS serotype
switching was seen. This is the first study attempting to establish a correlation between capsular
and LPS serotypes.
Materials and Methods
Bacterial Strains. All V. vulnificus isolates used in this study can be found in Table A.1. Each
isolate was grown in HI broth or HI agar containing 0.34 M NaCl at 30ºC unless otherwise
noted.
Continuous Passage Switching Assay. Vibrio vulnificus isolates were streaked on HI agar
plates and allowed to incubate at room temperature for 5 days. At the end of day 5, the plates
were screened for the presence of translucent or sectored colonies. If a true translucent colony
(Fig. 4.1) was observed, the colony was picked, designated as a translucent isolate and
cryopreserved for later analysis. If no translucents were observed, either sectored (Fig. 4.1) or
less opaque colonies would be picked, restreaked on HI, and allowed to incubate for 5 days at
room temperature. This process was continued indefinitely until a translucent for each isolate
was generated.
“Rocking” Switching Assay. This assay was performed as previously described by Grau et al.
(74) with the following modifications. Initial cultures were removed from storage at -70ºC and
grown overnight at 37ºC. Cultures were then streaked on mCPC agar and up to 5 isolated
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colonies were picked and transferred to separate tubes containing HI broth containing 0.34 M
NaCl. This resulted in each isolate having as many as 5 independent cultures used in the
switching assay. All cultures were grown in 3 ml volumes of HI in glass tubes, incubated at 30ºC
with shaking, and 5 daily passages constituted 1 cycle. At five days, cultures were diluted and
spread on HI plates, incubated at 30ºC, and observed for translucent colonies. Cultures were
terminated once a true translucent colony was isolated on a spread plate. The switching assay
was carried up to but not more than 3, 5 day cycles.
“Rolling” Switching Assay. This assay was performed exactly as described above in the
“rocking” assay except that cultures were incubated in a Labnet Problot Hybridization Oven
(Labnet International, Inc., Woodbridge, NJ) while rotating at max speed on a multi-purpose
horizontal rotor (Scientific Industries, Inc., Bohemia, NY).
Whole-Cell ELISA. Whole-cell ELISAs were performed as described in Chapter 2 with the
following modification. Individual translucent colonies were picked and resuspended in 3 ml of
PBS. Fifty microliters of resuspended bacteria were placed in each well of an Immulon IV
ELISA plate and incubated at 37ºC overnight to dehydrate the well. All remaining steps of the
ELISA were carried out as previously described in Chapter 2.
Scoring of Colony Morphotypes. For the purpose of this study, isolates were scored as either
opaque, rugose, or translucent. While there were many colony variants observed in this study,
those that were not opaque or rugose (dry, wrinkly appearance) were classified as translucent.
Serially diluted plates were scored for the total number of colonies and the number of translucent
colonies present. Examples of the different colony morphotypes observed are shown in Figure
4.1.
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Colony morphotype microscopy. Photomicrographs of representative colony morphologies
were taken on a Nikon Microphot FXA light microscope (Nikon, Melville, NY).
Results
Continuous Passage on Agar Assay. It had been observed that translucent colonies had a
different LPS serotype compared to the parent opaque colonies (111) but no controlled study of
this phenomenon has been conducted. The primary observation was made following continuous
passage on agar. The LPS switching data following continuous passage is shown in Table 4.1,
column 1. Fifteen isolates were examined in this assay. Seven isolates changed LPS serotypes
and eight isolates remained unchanged. All isolates whose LPS serotypes changed, switched to a
serotype that was recognizable by one of the seven anti-LPS MAbs. In this assay, translucent
morphotypes were typed as either O1, O5, or O1/O5 providing evidence that serovars O1 and O5
are independent of each other. Nearly 47 % of the isolates examined in this assay had a change in
their LPS serotype as compared to 53% of the isolates that remained the same. Of the seven LPS
serotypes that were present in the opaque morphotypes, the majority of those seven serotypes
were not present in the translucent morphotypes. Analysis of the assay showed a distinct pattern.
The resulting translucent LPS profiles showed that serovar O5 was the dominant resulting LPS
type in translucent colonies with 67% of the resulting translucent morphotypes expressing it.
“Rocking” Assay. While the continuous passage study was in progress, Grau et al. (74) reported
that cultures incubated with rocking resulted in multiple morphotypes. Isolates of known
serotypes were cultured according to the method of Grau et al. (74). As reported, this method
generated multiple morphotypes, but little change in LPS serotypes was observed (Table 4.1).
Figure 4.1 shows the varieties of colony morphotypes observed over the course of this
experiment, including sectored, rugose, translucent, and intermediates between opaque and
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Table 4.1. Comparison of LPS switching assays.
Isolate
1002
1007
1009
1866
1013
CDC 9032-95
ATL-9579
CDC 9062-96
JY1701
CDC 9029-95
1001
1014
549
CDC 9031-96
98-640 DP-E9
99-796 DP-E7
99-742 DP-A9
CDC 9075-96
1005
C7184
05-130
541(Ø)-49c
CDC 9057-96
Biotype 3/12
JY1305
A8
1004
938
1000

Continuous Passage on Agara
Opaqueb
Translucentc
O1/O5 (1)
O1/O5 (1)
O1/O5 (1)
wdO1/O5(1)
O1/O5 (1)
O1/O5 (1)
O1/O5 (1)
O1/O5 (1)

O2 (1)

O5 (1)

O2 (1)
O2 (1)

O2 (1)
O5 (1)

O3 (1)
O3 (1)

O5 (1)
wO3/wO1/O5 (1)

Rockinga
Opaqueb
Translucentc

O1/O5 (1)

O1/O5 (20)

O2 (4)

O2 (16)

O3 (4)

O4 (1)
O4 (1)

O3 (15)
wO3 (1)

Rollinga
Opaqueb
Translucentc
O1/O5 (1)
O1/O5 (5)

O1/O5 (1)
O1/O5 (1)
O1/O5 (1)
O1/O5 (1)
O1/O5 (1)
O1/O5 (1)
O2 (1)
O2 (1)

O1/O5 (5)
N/Ae
O1/O5 (5)
N/A
N/A
N/A
O1/O5 (5)
N/A

O2 (2)
O2 (1)
O2 (1)
O2 (1)
O2 (1)
O2 (1)
O3 (2)

O2 (2)
O2 (5)
O2 (5)
O2 (5)
O2 (1)
O2 (1)
O3 (5)

O3 (1)
O3 (1)
O3 (1)
O3 (1)
O3 (1)
O3 (1)
O3 (1)

O2 (5)
O3 (2)
N/A
O3 (1)
NTf (5)
N/A
O3 (3)

O4 (1)

NT (4)
wO4 (1)

wO4/O5 (1)
O4/wO6 (1)
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Table 4.1. (cont.).
Isolate
89-142
CDC 9026-95
94-8-112
MLT 141
CDC 9070-96
OLOL-2
938
CP Sed 5
1003
1003 (T)
1003 (R)
1003 (T) epi1010
94-226 B
9346-95
1008

Continuous Passage on Agara
Opaqueb
Translucentc

O6 (1)

O6 (1)

O6 (1)

O6 (1)

O7 (1)

Rockinga
Opaqueb
Translucentc

O6 (2)

O6 (8)

O6 (1)

O6 (1)

O7 (1)

MLT 141NT

NT (5)

O6 (1)
O7 (5)
O7 (5)
O7 (5)
O7 (5)

O6 (1)
N/A
O7 (25)
O7 (25)
O7 (24)
O7/wO6(1)

NT (1)

NT (5)

NT (15)
wO6 (3)
wO4 (2)

1466
NT (1)
O1/O5 (1)
1657
NT (1)
NT (1)
541(Ø)-84C
a. Method of culturing strains during switching assay. Some strains were tested using multiple culturing methods.
b. Starting serovar. Number of colonies tested is shown in parenthesis.
c. Final serovar. Number of colonies tested is shown in parenthesis.
d. w = weak interaction defined as two times the negative control plus 0.1-0.3 ODU
e. N/A = no change in colony opacity.
f. NT = nontypeable.
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Rollinga
Opaqueb
Translucentc
O4 (1)
O4 (5)
O4 (1)
O4 (5)
O4 (1)
O4 (5)
O4 (1)
NT (5)
NT (1)
N/A
O4 (1)
N/A
O4 (1)
NT (5)
O4 (1)
N/A
O4 (1)
O4 (1)
O6 (1)
O6 (1)
O6 (1)
N/A

FIG. 4.1. Colony morphologies observed in LPS switching assays. Colonies scored as translucent
are in column 1 and colonies scored as opaque are in column 2.
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translucent. For the purpose of this study, all colonies that were neither opaque nor rugose were
considered translucent. None of the translucent isolates observed in this study changed their LPS
serotype as compared to their parental opaque variant. The only change that was observed was
isolate MLT 141NT, which either remained the same or became a weak O6 or a weak O4
serotype as compared to the strong O4 expression of the opaque variant (Table 4.1, column 2).
While this assay was not effective in changing LPS serotypes, it was very effective for causing
rapid switching from opaque to translucent morphotypes, with 64% of the opaque isolates
producing translucent colonies in the first cycle.
“Rolling” Assay. The rocking method resulted in a culture gradient, probably due to oxygen
availability. In order to generate cultures with consistent oxygenation, isolates were cultured in a
near horizontal rolling culture system. This assay was performed similarly to the rocking method
except that the culture tubes were incubated on an angle providing better aeration for the culture.
While the rolling assay yielded fewer colony morphotypes (opaque, halo, button, and
translucent) on spread plates as compared to the rocking assay, the rolling assay was successful
in generating LPS serotype switching in 17.5% of the isolates tested (Table 4.1, column 3). The
serotypes of the resulting translucent colonies were not dominated by the O5 serotype as seen in
the continuous passage on agar assay. Strain 1001 (a LPS serotype O2 isolate), however, was
observed to switch to LPS serotype O5 in both the continuous passage on agar and the rolling
assay (Table 4.1, columns 1 and 3).
Summary of LPS Switching Assays. Upon colony switching from an opaque to a translucent
morphotype, a colony either retained the same LPS serotype, changed to a known LPS serotype,
switched to an undefined LPS serotype, or even possibly lost its O-side chains. Analysis of the
LPS switching data provided in Table 4.1 showed patterns in LPS switching. When switching
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occurred, there appeared to be a unidirectional relationship among the LPS serotypes during the
switch from an opaque to a translucent colony morphotype. A proposed relationship amongst the
LPS phenotypes is shown in Figure 4.2. All of the relationships proposed in Figure 4.2 were
supported by the data in Table 4.1 except for the correlation between serovar O5 and O6 which is
hypothetical as of this time.
Discussion
The idea that colony opacity correlates with virulence in V. vulnificus has long been
established (72, 73, 150). While others have observed capsular variants in V. vulnificus (72-74,
77, 79, 150), or capsule switching in other bacteria (151-155) no one has shown a correlation
between capsule variation or switching and a change in LPS structure. Here I described several
different culture methods utilized to drive colonies from an opaque to a translucent morphotype
in order to induce LPS switching simultaneously with the production of capsule variants. The
first method used was the continuous passage of the bacterium on solid agar. While this method
was time consuming, it always generated translucent morphotypes and in some cases a change in
LPS structure as well (Table 4.1).
Grau et al. (74) described a culture method designed to induce high-frequency phase
variation in V. vulnificus. This technique was utilized in this study in an effort to rapidly produce
translucent morphotypes from opaque parent colonies. This “rocking” technique was extremely
successful with producing colony variants, including translucent colonies, but none of the
resulting translucent morphotypes expressed a different LPS serovar when compared to the
parent colony. The one exception, was strain MLT 141NT, an untypeable serotype, that did pick
up either a weak O4 or a weak O6 serotype reactivity (Table 4.1). One of the interesting effects
of culturing V. vulnificus utilizing this method was the production of several colony morphotypes
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NT

O3

NT

O7
O1
O5

O2

O4

O5

O6

NT

FIG. 4.2. Proposed relationships of LPS serotypes as determined through opaque to translucent
colony switching assays. All LPS branches converge on serovar O5 except for serovar O7. The
dotted line between serovars O5 and O6, and O7 and O6 represents a proposed relationship. NT
represents nontypeable serovars.
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as seen in Figure 4.1. Each colony morphotype represented is probably indicative of a different
level of capsular expression. While the rocking method was efficient for producing colony
variants, it was largely unsuccessful in generating LPS variants. A possible explanation for the
lack of LPS variants was probably due to the short amount of time needed to produce capsule
variants as compared to other methods; thus limiting the number of generations needed to
acquire sufficient genetic mutations to produce a change in LPS structure.
To increase aeration of the culture, cultures were incubated in a near horizontal position
with continuous rolling. The “rolling” method provided minimal variations in colony
morphotypes (opaque, intermediate, and translucent) and a higher percentage of LPS switching
as compared to the “rocking” method. In order to obtain translucent morphotypes utilizing the
“rolling” method, the majority of the cultures were carried into the 2nd and 3rd cycles of the
assay. The increase in the number of generations needed to produce translucent colonies in the
“rolling” method as compared to the “rocking” potentially allowed for the “rolling” isolates to
acquire more mutations leading to an increased chance of generating a LPS variant.
Unfortunately, none of the methods used to generate LPS variants utilizing colony
opacity as an indicator were over 50% successful. However, there were many interesting patterns
that developed over the course this study. The most interesting observation to develop from each
of the three LPS switching assays was that the changes in LPS serovars could be arranged into
two distinct patterns. One pattern had serovar O3 going to serovar O5 through a nontypeable, an
O2, and an O1 serovar, while the other pattern had serovar O4 going to serovar O5 through a
nontypeable serovar (Fig. 4.2). When the patterns were aligned, it became clear that as isolates
changed colony morphologies from opaque to translucent, some isolates’ LPS type changed in a
unidirectional pattern with the two branches converging on serovar O5. No isolate changed its
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LPS antigens to a previous serovar on an LPS pathway (Fig. 4.2). A possible explanation is that
serovar O5 is a core polysaccharide that the other serovars use as a base framework from which
to develop a functional O-side chain. While there was enough data generated from serovars O1
to O5 to generate an LPS model, there was not enough evidence to accurately place serovars O6
and O7 on the model. The current LPS model shown in Figure 4.2 was designed with serovar O6
on the right of serovar O5 because of the resistance of the O6 LPS serovar to change and the
multiple appearances of weak O6 serotypes from other LPS serovars (Table 4.1). However, other
serovars, particularly serovar O4 and one case of O7 were shown to pick up a weak O6
phenotype upon switching to a translucent phenotype. Alternatively, serovar O6 could be placed
on the O4 pathway immediately to the left of serovar O5 with serovar O7 either on the O4
pathway or its own pathway converging on O6. Much more data will have to be generated in
order to confirm the relevance of this LPS model. However, these nontypeable species might be
useful in generation of new serotyping reagents.
Three previous studies have examined opaque, translucent, and intermediate colony
morphotypes: Finkelstein et al. (76) in V. cholerae and Rosche et al. (77) and Hilton et al. (156)
in V. vulnificus. In the Rosche et al. study, emphasis was placed on genetic analysis of the
various morphotypes observed in the study. While they identified the wzb gene which encodes a
phosphatase required for capsule expression, as an essential gene for capsule production, they
also observed translucent colony morphotypes that were wzb+, indicating that other factors are
involved in the opaque to translucent switch as well. These other factors were not addressed in
their original paper. A later study by Hilton et al. (156) found that both temperature and aeration
played an important role in the generation of translucent morphotypes from opaque strains. In
my study, colony variants were observed at both room temperature and 30ºC, but there was a
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higher frequency of switching from opaque to translucent colonies observed in the “rocking”
assay as compared to the “rolling” assay. The data generated from the “rocking” and “rolling”
methods utilized in this study were in agreement with the findings of Hilton et al. (156) who
found that aeration played a role in capsule switching. In their study, they observed a higher
frequency of switching with their E-type (environmental) as compared to their C-type (clinical)
isolates. This data did not agree with the data in my study which showed that clinical and
environmental isolates switch with the same frequency (84% versus 83%, respectively). In
addition to the observations made by Hilton et al. (156), I found that of the isolates that
underwent capsule switching, some changed their LPS phenotype. Interestingly, I found that
clinical isolates were much more likely to change their LPS (75%) as compared to environmental
isolates (25%) (Table 4.1). These data provide evidence that LPS serovar changes are not
directly related to capsule switching. Due to the small the number of isolates examined by Hilton
et al. (156) and the few isolates that switched LPS phenotypes in my assays, more isolates will
have to be examined to see if there is indeed a significant difference in capsule and LPS
switching in clinical versus environmental isolates.
The data generated in this study clearly indicated that differing culture conditions
produce different colony morphotypes. The continuous passage on agar assay and the “rolling”
assay both generated colony morphotypes that were generally opaque and translucent in
appearance, whereas the “rocking” method produced as many as nine visually distinct colony
morphotypes as shown in Figure 4.1. The most obvious difference between the “rocking” and
“rolling” techniques was the level of aeration that each culture obtained. In the “rolling” method,
oxygen was constantly being introduced to the medium and the nutrients were constantly being
evenly distributed in the culture medium resulting in an even distribution of oxygen and nutrients
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throughout the culture. In the “rocking” method, oxygenation would only have occurred at the
air/water interface resulting in higher levels of oxygen at the surface and lower levels of oxygen
in the deeper levels of the medium. Since V. vulnificus is defined as a facultative anaerobe, the
bacteria would have selectively grown in the strata with the highest levels of oxygen utilizing all
available nutrients in that strata, first. Over time, the organism would have had to become
microaerobic, utilizing the nutrients available in the less oxygen rich environments. In order to
adapt to a new environment, different genes would be expressed to allow the bacterium to
survive under these conditions. It is entirely possible that one or more of these genes may be
responsible for change(s) in the capsule, and consequently changes in colony morphotypes.
Due to the genetic complexity that exists for both capsule and LPS biosynthesis, it is
impossible to speculate at this time whether or not there is any correlation between capsule
variation and LPS switching. The possibility does exist that if a common gene for both capsule
and LPS biosynthesis is mutated, changes in both the capsule and LPS would be observed.
However, while many of the genes have been identified for capsule (77, 150, 157-160) and LPS
production (126) many more have yet to be determined. Currently, the genes shared by both
biosynthetic pathways have not been defined. It is possible that LPS-defined opaque and
translucent colonies identified in this study may be useful in the future analysis of these
pathways.
While there appeared to be little to no correlation between capsule variants and LPS
switching, there is no doubt that culturing techniques plays a large role in the regulation of the
capsule in V. vulnificus. A recent study in V. vulnificus has shown that the regulation of capsule
biosynthetic genes wza and wzb were linked to temperature (158), but that the bacterium had to
be maintained at a maximum of 14ºC for as long as 14 days before wza and wzb were
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undetectable in two out of the three isolates examined. Down regulation and up regulation of
these genes may be involved in colony morphotypes as suggested by Rosche and Oliver (77).
All cultures used for wza and wzb analysis in the Rosche and Oliver paper (77) were incubated at
22ºC which is higher than 14ºC. The fact that Rosche and Oliver, identified isolates that were
wzb- at 22ºC suggests that regulation of this gene is not based solely on temperature. The data
from Rosche and Oliver (77) and Smith and Oliver (158) seem to agree with my findings that
capsule variation is not dependent on temperature, and that oxygen levels are probably more
important. Interestingly, the percent oxygenation of water is related to water temperature in the
environment, as elevated temperatures decrease the level of dissolved oxygen. While the data
from Hilton et al. (156) and the data presented in this study support the hypothesis that aeration
is important in producing colony morphotype variants, future experiments will still be needed to
determine the genes involved in the capsule switching mechanism, and what other factors may
be involved in this change as well. While capsule switching is an interesting phenomenon, the
data presented here clearly indicate that changes in capsule and LPS are only indirectly related
and that changes in colony morphotypes should not be used an indicator for LPS switching.
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CHAPTER 5:
CONCLUDING REMARKS
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The overall goals of this study and other research on sub-typing systems are to more
rapidly identify pathogenic sub-types of V. vulnificus and to generate a more complete
epidemiological understanding of the distribution of V. vulnificus, lowering the risk of V.
vulnificus food infection. Many different classification systems have been studied including
colony morphotyping, serotyping, biotyping, ribotyping, and genotyping. In this study, I
generated new serological reagents and evaluated the effectiveness of LPS serotyping using these
reagents. Shimada and Sakazaki (87) originally hypothesized that there are seven LPS serovars
for V. vulnificus. In 1991, Martin and Siebeling (86) used MAbs to identify five of these
hypothesized serovars. In this study, I developed two additional MAbs that identify another two
LPS serovars termed O6 and O7. This panel of seven MAbs to LPS increases the overall typing
of V. vulnificus isolates by almost 4%. Although I can now recognize seven serovars, this study
shows that 25% of the V. vulnificus isolates are still nontypeable, indicating that more serovars
exist than was previously thought.
The distribution of LPS O-side chain variants of V. vulnificus is different for isolates of
clinical and environmental origins. The panel of LPS MAbs was more efficient for
epidemiological tracking of clinical isolates (84.6% typeable) than for environmental isolates
(61.6% typeable). This was not surprising as all of the isolates used as immunizing strains were
collected from clinical sources. In this study LPS serovar O1/O5 was the most prevalent serovar
in typed clinical isolates but was observed less frequently in environmental isolates. Perhaps
most significant, the O1/O5 serovar was not detected in isolates outside the United States. For
isolates from the United States 38.7% of the clinical isolates were of the O1/O5 serovar,
compared to just 3.4% of the environmental isolates. The high prevalence of serovar O1/O5 in
clinical isolates may suggest that LPS serovar O1/O5 may have a greater potential for virulence
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than other serovars. Alternatively, since LPS phenotype was shown to change, it is possible that
many serovars can infect human beings, but that growth in patients results in a selection for the
O1/O5 phenotype. Prevalence studies, like that conducted in this dissertation will not address
this question. Future studies should include animal studies to determine if phenotype changes are
a result of mammalian infection.
The original purpose of the work by Martin and Siebeling (86) was to develop a subtyping system to track human V. vulnificus cases and to identify the source of the infection. Their
study design used a panel of clinical isolates for generation of antibodies. One of the inherent
problems with the current design of this LPS typing system is that all of the isolates used as
immunizing strains were exclusively from clinical sources. The addition of two additional typing
reagents for LPS increased the overall typing of V. vulnificus isolates; however the results of this
study demonstrated that there were more than the seven LPS serovars proposed by Shimada and
Sakazaki (87) and Martin and Siebeling (86). In addition, there is the possibility that the LPS
phenotype may change with replication or under certain culture conditions. This further
complicates the use of LPS serovars as a sub-typing system.
The traditional production and maintenance of MAbs to type the different LPS serotypes
is both costly and time consuming. The available PDAb systems were developed to generate
new, inexpensive reagents to known, usually pure antigens. The resulting phage are generally
pools of phage that bind the target antigen. In these systems, the target antigen is usually a
protein; however, previous work has shown that PDAb can be made to bacterial LPS (135). To
date, no one has used PDAb for typing or sub-typing strains or isolates of bacteria. In Chapter 3,
I showed that the existing MAb secreting hybridomas can be used to generate PDAbs and can be
used as an alternative system for the maintenance of existing MAbs. I chose the pComb3X
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system which generates a single scFv sequence through an overlap PCR to use as the phagedisplay system because it had been used to generate murine-source PDAb (134-136). In my
hands, the published primers (137) did not generate a scFv overlap because of palindromic
sequences on the 3’ end of the overlap primers that resulted in primer dimer formation. I
designed new primers and successfully generated and amplified scFv genes from MAb, RS1. I
was able to successfully generate and a PDAb, PJ1, that successfully displayed the Fv region of
RS1 and recognized the O6 LPS serovar from V. vulnificus strain 1003 (O) in a manner similar to
RS1.
The new primers designed in this study can be used for both the conversion of preexisting MAbs to the more cost-effective phage-display system and generation of future PDAbs.
For long term storage, MAb producing hybridomas must be stored in liquid nitrogen. This is
both costly and time consuming and many useful and important hybridomas have been lost due
to failures in liquid nitrogen storage systems. I used the phage-display system as an alternative
means of maintaining an important MAb, but it should be noted that the system was designed to
clone a cDNA library into a phagemid with the goal of selecting a specific PDAb from the
population. In the future, researchers can use a mixture of V. vulnificus isolates for
immunizations of mice, followed by the isolation of cDNA from splenocytes and generation of a
PDAb library. The resulting phage library should contain rearranged immunoglobulin DNA
specific for the immunizing strains. Ideally, this technique could be used to rapidly identify new
serovars, minimizing the number of lab animals needed to complete a typing system, and ending
the need and expense of cell culture.
When freshly isolated, V. vulnificus colonies demonstrate a typical opaque morphotype.
Following long term culture in vitro, it has long been known that translucent morphotypes will
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spontaneously appear (83, 150). These translucent morphotypes have little or no capsule
production compared to their opaque parents and also show decreased pathogenicity in mouse
infection studies (72, 73). Changes in capsular structure were determined using changes in V.
vulnificus colony morphotypes from opaque to translucent phenotypes on solid media. In the
switching assay, I found that the culturing method used dictated how many capsular variants
were observed. While the continuous passage of an isolate on solid agar generated capsular
variants, it was slow, often taking weeks to produce a translucent colony from an opaque parent.
To speed the process, sub-culturing was conducted in broth. I used using either the “rocking” or
“rolling” assays described in Chapter 4. These broth-based methods generated translucent
colonies, but resulted in a wider variation in the colony morphotypes. The “rocking” assay
produced the most colony variants, including opaque, translucent, rugose, and intermediate
morphotypes, producing more colony variants than the other culturing methods employed in this
study. I believe rocking induces higher rates of capsular change because the method results in an
oxygen and nutrient gradient in the tube.
It was observed in the laboratory of R.J. Siebeling that following long-term culture on
solid agar, translucent forms could have a different LPS serotype than their opaque parent. This
led to the hypothesis that LPS and capsule expression may be linked. To test the hypothesis that
changes in LPS serotype was linked to changes in capsule expression, I used the three different
culturing methods to generate the capsular variants. I tested a parent colony from strains of
different LPS serotypes and then tested multiple translucent morphotypes that resulted following
culture of that colony. In 73.2% of the isolates examined, the LPS phenotype remained the same
while in 26.8%, a change was observed in the LPS phenotype. The observed change in serotype
was due to either a switch to a different serovar, for example an O3 to an O1/O5, or a change to a
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nontypeable phenotype. The nontypeable result could have been due to either the loss of LPS
side chains or to a change to a phenotype for which I did not have reagents. The majority of
strains that resulted in LPS serotype changes were recovered from long-term culture on solid
agar. This suggests that the change in LPS serotype may be the result of mutations that occur
during long-term culture. The generation of both capsule and LPS is under the control of
multiple genes and the two pathways are overlapping. It is possible that the changes in capsule
production and LPS serotype are indirectly related. This should be examined in future studies.
This study does argue for studying and typing isolates of V. vulnificus for diagnostic purposes in
the fewest passages possible.
These results suggest that capsular phenotype is not directly related to changes in LPS
serotype since the majority of the resulting translucent morphotypes did not show changes in
LPS serotype; however, I did observe that when V. vulnificus became translucent, the changes in
LPS produced unique patterns. All of the strains that showed changes in their LPS phenotypes
provided evidence for two LPS branching pathways, one that started with O3 and one that started
with O4. There were no examples of isolates that changed to O3 or O4 serotypes. Based on these
results, I propose a model where LPS switching occurs in a unidirectional manner that converges
on serovar O1/O5 (Fig. 4.2). Taken together, these data indicated that LPS switching occurs and
is unidirectional. I propose that serovar O1/O5 is probably a common LPS epitope from which
most other serovars, are derived. Switching was not observed in the serovars O6 and O7 isolates
tested. Because there were so few O6 and O7 isolates to test, it is difficult to determine where
they belong on the LPS model. In several cases, a weak O6 reactivity was observed in addition to
other serotypes in tested translucents. It is possible that O6 may represent a “core” epitope.
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The results suggest that while LPS phenotype changes occur, they are not linked directly
to capsule production. Future work should include testing of many more isolates, but should also
include the testing of non-translucent morphotypes as well. It may be possible to induce random
mutations in V. vulnificus for further LPS studies by either generating auxotrophic mutants,
exposing the cells to chemical mutagens such as acridine orange, or using insertional transposons
to disrupt genes. The resulting mutants could then be examined for changes in LPS phenotype. In
addition to addressing the pattern of LPS phenotype change, this type of study might also help
identify the gene(s) responsible for the observed changes.
With the development of the two new serovars O6 and O7, this study has shown that the
current LPS serotyping system is adequate for epidemiological analysis of clinical isolates but
the percentage of nontypeable isolates is still substantial. Lipopolysaccharide serotyping is not an
ideal stand-alone typing system due to the lack of stability of the LPS epitope (Chapter 4) and
the greater number of LPS serovars than previously thought (Chapter 2). Future work should
include generation of new LPS typing reagents to account for the majority of V. vulnificus LPS
serotypes. Delineating the pathways of serotype transition may be an important step in
identifying other potential V. vulnificus serotypes. Generation and maintenance of serotyping
reagents could be made more economical by using the phage-display system (Chapter 3). Phagedisplayed antibodies offer a cost-effective method for the development and maintenance of
antibody-based typing systems against V. vulnificus and will increase the likelihood that
pathogenic sub-types will be identified.
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Table A.1. Sources of bacterial isolates.
Strain
535
536
1456
1674

Country
Sweden
Sweden
USA
Unknown

Source
Eels, Diseased
Eels, Diseased
Unknown
Unknown

Donor (ref)*
Amaro, Carmen
Amaro, Carmen
Siebeling, Ronald
Siebeling, Ronald

05-130

LA, USA
Lake Pontchartrain
LA, USA
LA, USA
LA, USA
LA, USA
LA, USA
LA, USA
LA, USA
LA, USA
LA, USA
LA, USA
LA, USA
LA, USA
LA, USA
USA
Unknown
USA
USA
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
Unknown
USA
USA
USA
USA

Unknown

Siebeling, Ronald

Stool Culture
Blood Culture
Blood Culture
Wound Infection
Stool Culture
Blood Culture
Blood Culture
Stool Culture
Blood Culture
Blood Culture
Blood Culture
Blood Culture
Blood Culture
Unknown
Unknown
Unknown
Unknown
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Unknown
Red Drum
Red Drum
Red Drum
Unknown

Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald (86)
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Janes, Marlene
Siebeling, Ronald
Hawke, John
Hawke, John
Hawke, John
Thune, Ron

1000 (O)
1001 (O)
1002 (O)
1003 (O)
1004 (O)
1005 (O)
1007 (O)
1008 (O)
1009 (O)
1010 (O)
1013 (O)
1014 (O)
1015 (O)
1466 (O)
15-8-161
1657 (O)
1866 (O)
29M
541(Ø)-14C
541(Ø)-2A
541(Ø)-2AC
541(Ø)-2C
541(Ø)-2O
541(Ø)-32C
541(Ø)-44C
541(Ø)-49C
541(Ø)-54C
541(Ø)-57C
541(Ø)-68C
541(Ø)-69C
541(Ø)-7C
541(Ø)-84C
541(Ø)-9C
549 (O)
89-142
89-332
89-441
90-247
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Table A.1 (cont.).
Strain
916i
916c
916d
916f
92-271
938 (O)
94-225B
94-226B
94-8-112
94-9-123
95-10-15
95-8-161
95-8-162
95-8-188
95-8-6
95-8-6A
960717-1/2F
960926-1/4C
96-7-155
96-7-156
97-1-119
97-1-20
98-624 DP-C9
98-640 DP-E9
98-641 DP-G8
98-783 DP-A1
99-509 DP-A6
99-520 DP-B8
99-537 DP-G7
99-540 DP-B6
99-581 DP-C7
99-584 DP-B12
99-609 DP-A4
99-622 DP-E4
99-623 DP-F5
99-624 DP-C10
99-645 DP-C4
99-736 DP-C7
99-738 DP-B5
99-742 DP-A9
99-743 DP-B6
99-779 DP-D2
99-780 DP-E1
99-796 DP-E7
A8
ATL-9572
ATL-9579

Country
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
LA, USA Gulf
USA
Unknown
USA
USA
Denmark
Unknown
Unknown
Denmark
Denmark
Unknown
Unknown
Unknown
Spain
Spain
Unknown
Unknown
Unknown
Unknown
USA
LA, USA
LA, USA
LA, USA
TX, USA
RI, USA
MD, USA
TX, USA
LA, USA
TX, USA
OR, USA
TX, USA
FL, USA
TX, USA
TX, USA
FL, USA
FL, USA
MS, USA
TX, USA
LA, USA
LA, USA
FL, USA
Spain
FL, USA
TX, USA

Source
Oysters
Oysters
Oysters
Oysters
Mummichog
Danish Eel isolate
Red Drum
Red Drum
Wound Infection
Unknown
Unknown
Eels, Eel Farm
Eels, Diseased
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Oysters
Eels, Diseased
Clinical, Recovery
Clinical, Recovery
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Donor (ref)*
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Hawke, John
Siebeling, Ronald (12)
Hawke, John
Hawke, John
Amaro, Carmen (161)
Amaro, Carmen (161)
Siebeling, Ronald
Amaro, Carmen (162)
Amaro, Carmen (162)
Siebeling, Ronald
Siebeling, Ronald(161)
Amaro, Carmen
Amaro, Carmen
Amaro, Carmen
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
DePaola, Angelo (16)
Amaro, Carmen
DePaola, Angelo (16)
DePaola, Angelo (16)

Table A.1 (cont.).
Strain
ATL-9580
ATL-9824
Az
Biotype 3/1033
Biotype 3/12
C7184 (O)
CDC 9003-97
FLA 9509
CDC 9005-97
DAL 7-9087
CDC 9026-95
LOS 6808

Country
TX/LA, USA
TX, USA
Spain
Israel
Israel
Unknown

Source
Clinical, Fatality
Clinical, Recovery
Eel Tank Water
Blood Culture
Blood Culture
Unknown

Donor (ref)*
DePaola, Angelo (16)
DePaola, Angelo (16)
Amaro, Carmen (162)
Amaro, Carmen (161)
Amaro, Carmen(161)
Oliver, James(163)

LA, USA

Clinical, Fatality

DePaola, Angelo (16)

LA, USA

Clinical, Recovery

DePaola, Angelo (16)

USA

Unknown

DePaola, Angelo

CDC 9029-95
ORL 8073
CDC 9030-95
ORL 1506
CDC 9031-96
ATL 6-1306

FL, USA

Clinical, Recovery

DePaola, Angelo

FL, USA

Clinical, Recovery

DePaola, Angelo (16)

FL, USA

Clinical, Recovery

DePaola, Angelo (16)

CDC 9032-95
ORL 8074
CDC 9038-96
LOS 7318

TX, USA

Clinical, Recovery

DePaola, Angelo (16)

TX, USA

Clinical, Fatality

DePaola, Angelo (16)

CDC 9047-96
LOS 7506
CDC 9049-96
ATL 61438(12)
CDC 9053-96
FLA 8869
CDC 9057-96
DAL 8-9131(7)
CDC 9060-96
DAL 7-9002

TX, USA

Clinical, Recovery

DePaola, Angelo

TX, USA

Clinical, Fatality

DePaola, Angelo

TX, USA

Clinical, Recovery

DePaola, Angelo (16)

TX, USA

Clinical, Fatality

DePaola, Angelo

TX, USA

Clinical, Fatality

DePaola, Angelo (16)

CDC 9062-96
LOS 7343
CDC 9067-96
DAL 7-9000
CDC 9070-96
DAL 79040
CDC 9074-96
ATL 71491
CDC 9075-96
ATL 71503

LA, USA

Clinical, Fatality

DePaola, Angelo (16)

TX, USA

Clinical, Fatality

DePaola, Angelo (16)

TX, USA

Clinical, Recovery

DePaola, Angelo (16)

TX/LA, USA

Clinical, Fatality

DePaola, Angelo (16)

FL, USA

Clinical, Fatality

DePaola, Angelo (16)

CDC 9076-96
ATL 71504
CDC 9149-95
NSV-5829

LA, USA

Clinical, Recovery

DePaola, Angelo (16)

FL/LA, USA

Clinical, Recovery

DePaola, Angelo (16)
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Table A.1 (cont.).
Strain

Country

Source

Donor (ref)*

CDC 9340-95
ORL 8324
CDC 9342-95
LOS 6966
CDC 9345-95
DAL 6-5000
CDC 9346-95
BUF 7211
CDC 9348-95
NSV 5830
CDC 9349-95
NSV 5736
CDC 9352-94
ATL 9823
CDC9039-96
LOS 7343
CECT 4604
CECT 4606
CECT 4863
(ATCC 33817)
CECT 4867
CECT 4869
CECT 5198
CECT 529
(ATCC 27562)
CECT 5343
CECT 5762
CG100
CMC-P6
CP Clam 2 (O)
CP Mussel 10
CP Sed 5 (O)
FB Oyster 11 (O)
JY 1305
JY 1701
LSU 1866
MLT 124 (O)
MLT 125 (O)
MLT 131 (O)
MLT 133 (O)
MLT 136
MLT 141 (O)
MLT 198 (T)
NOL-3727
9058-96
OLOL 1
OLOL 2

FL/LA, USA

Clinical, Fatality

DePaola, Angelo (16)

TX/LA, USA

Clinical, Recovery

DePaola, Angelo (16)

LA, USA

Clinical, Fatality

DePaola, Angelo (16)

FL, USA

Clinical, Fatality

DePaola, Angelo

FL, USA

Clinical, Recovery

DePaola, Angelo (16)

AL, USA

Clinical, Fatality

DePaola, Angelo (16)

LA, USA

Clinical, Fatality

DePaola, Angelo (16)

LA, USA

Clinical, Fatality

DePaola, Angelo (16)

Spain
Spain

Eels, Eel Farm
Eels, Diseased

Amaro, Carmen (161)
Amaro, Carmen

RI, USA

Wound Infection

Amaro, Carmen (161)

Unknown
Belgium
Spain

Eels, Diseased
Eels, Diseased
Eels, Diseased

Amaro, Carmen (162)
Amaro, Carmen
Amaro, Carmen (161)

USA

Blood Culture

Amaro, Carmen (162)

Spain
Spain
Taiwan
Unknown
USA
USA
USA
USA
Unknown
Unknown
Unknown
NJ, USA
NJ, USA
NJ, USA
NJ, USA
USA
NJ, USA
VA, USA

Eels, Diseased
Eels, Healthy
Oysters
Clinical
Oysters
Oysters
Sediment
Oysters
Unknown
Unknown
Unknown
Oysters
Oysters
Oysters
Oysters
Unknown
Oysters
Sediment

Amaro, Carmen (162)
Amaro, Carmen (162)
Amaro, Carmen (162)
Oliver, James
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Oliver, James
Oliver, James
Oliver, James
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald
Siebeling, Ronald

USA

Unknown

DePaola, Angelo

Baton Rouge, LA, USA
New Orleans, LA, USA

Blood Culture
Blood Culture

Cassanova, Todd
Cassanova, Todd
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Table A.1 (cont.).
Strain
SFGM
SRC 10215

Country
USA: Gulf of Mexico
Unknown

Source
Diseased Spade Fish
Unknown

* source of strain with citation if known
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Donor (ref)*
Thune, Ron
Oliver, James

Table A.2. Monoclonal antibodies used in LPS serovar identification of V. vulnificus.
Monoclonal Designation
Isotype
LPS Serovar Specificity
SM 1
IgG3 Kappa
O1 (O1/O5)
SM 4
IgG3 Kappa
O2
SM 11
IgG3 Kappa
O3
SM 31
IgG3 Kappa
O4
SM 46
IgG2a Kappa
O5 (O1/O5)
RS 1
IgG1 Kappa
O6
RS 2
IgG3 Kappa
O7
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